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Introduction:  Patients in the intensive care unit have complex haemostatic changes, 
which may be either procoagulant or anticoagulant.  Global assays may reflect a 
patient’s net haemostatic balance and can contribute to pro- or anti-coagulant 
assessment.  In this project, global assays were used to investigate both coagulation 
and fibrinolysis in samples taken from intensive care unit patients.     
 
Materials and Methods:   Comparative clotting analysis was carried out on whole 
blood and plasma samples from twelve samples from intensive care unit patients.  
Nine haemophiliac samples and 14 healthy individual samples were used as controls.  
Several assays were used to assess coagulation in these sample groups.  These 
included coagulation screens, individual factor assays and global assays [calibrated 
automated thrombography, whole blood and plasma low- dose tissue factor activated 
rotational thromboelastometry and the clot formation and lysis assay].   
 
Results:  Clot initiation in both whole blood and plasma analysis was prolonged in 
the intensive care unit samples.  This was observed in the global assay analysis and 
was elucidated by the standard laboratory tests such as the clotting screens and the 
individual factor assays.  However, once initiation commenced, the intensive care 
unit samples showed a clot formation comparable to that seen in healthy volunteers. 
 
Conclusion: Clot formation in intensive care unit patients is abnormal compared to 
that observed in healthy volunteer samples.  Several factors such as the fibrinogen 
and procoagulant factors influence coagulation and the rate of thrombin production.   
The clot stability in intensive care unit samples was found to be more robust in 
comparison to that observed in the healthy volunteer sample group.  This study 
showed that the initiation of coagulation is delayed intensive care unit patient 
samples but, once started, clot formation was comparable to that in healthy volunteer 
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1.1 VASCULATURE: HAEMOSTATIC RESPONSE TO INJURY 
 
 
Haemostasis, a dynamic process consists of two phases, the primary and 
secondary phase.  Primary haemostasis involves platelet adhesion to a site of 
vessel wall damage, initiating the formation of a platelet plug.  In order for this 
plug to stabilise, secondary haemostasis is necessary, whereby soluble 
coagulation factors assemble on the surface of adhered blood cells, leading to 
the activation of coagulation pathways and the formation of fibrin in accord 
with local conditions.  Most assays are designed to investigate abnormalities in 
this dynamic system  to highlight consequences these abnormalities might 
cause. 
 
Injuries to vessels cause platelet and coagulation responses that correlate with 
the degree of injury caused by rectifying the injury without obstructing the 
vessel.  There are multiple mechanisms by which this process occurs.  
Endothelial cells (ECs) line the lumen of the blood vessels (Figure 1.1) 
creating an impermeable layer that prevents passive transfer of blood cells, 
except in the presence of inflammation.  Beneath these cells is the sub 
endothelial layer (tunica media) that contains several components which play a 








Unactivated platelets cannot bind to endothelial cells.  Any damage that is 
caused to the endothelial layer exposes the subendothelial matrix which is 
rapidly covered in stimulated platelets which soon degranulate.  In this matrix 
are components such as collagen IV, V and microfibrils that bind stimulated 
platelets and result in platelet aggregation.  Von Willebrand factor, vitronectin, 
fibronectin and thrombospondin all have receptor sites that facilitate platelet 
attachment.  All these activities lead to a cascade of events resulting in a 

















Figure 1.1a Platelet responses to vessel injury.  Platelets play a vital role in haemostatic 
responses to vessel wall injury and are influenced by several factors (e.g extrinsic 
TF/FVIIa and sub-endothelial components).  EC, endothelial cell; TF, tissue factor; Coll, 
collagen; VWF, von Willebrand factor; ADP, adenosine triphosphate; AA, arachidonic acid; TXA, 




1.2 REGULATION OF COAGULATION 
 
Maintenance of normal haemostasis is controlled through surface-expressed 
molecules on ECs, circulating inhibitors of plasma proteins and negative 
feedback mechanisms.  The main regulator of coagulation is AT (antithrombin) 
which inhibits thrombin, FXIa (Activated factor XI), FXa (Activated factor X) 
and FVIIa (activated factor VII).  AT is regulated by binding on to heparin 
sulphate proteoglycans on the EC surface where it forms a highly stable 
complex that traps the AT from the circulation.  Another regulator is TFPI 





















Intrinsic pathway amplification 
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The second domain of TFPI first binds FXa, and then the first domain binds 
FVIIa.  This prevents further FXa being generated via the extrinsic pathway.  
Approximately 80% of TFPI is regulated by binding to glycosaminoglycans on 
EC surfaces.  Only a small percentage circulates in plasma and this circulatory 
TFPI is regulated by binding to low density lipoproteins with its affinity 
enhanced in the presence of heparin, thus contributing to its regulation.        
 
Thrombin is efficient at physiological restoration of vascular injury.   Due to 
this there is an innate regulatory process that prevents uncontrolled 
coagulation.  Thrombin serves as both a procoagulant and an anticoagulant but 
this is regulated based on an intact endothelial layer.  Thrombin that is 
produced at the site of an intact endothelial layer binds to thrombomodulin 
expressed on ECs.  Thrombomodulin is a potent modulator of thrombin and a 
co-factor in the activation of PC (Protein C).  PC binds ECs via the endothelial 
protein C receptor and stimulates its activity by the thrombin-thrombomodulin 
complex.  The resultant activated PC degrades FVa (activated factor V) and 
FVIIIa (activated factor VIII), reactions that are upregulated by the co-factor 
protein S (Dahlback, 2000).   
 
Physiologically, both pro- and anti-coagulant mechanisms favour 
anticoagulation but when vascular damage occurs, anticoagulation is 
downregulated.  Despite this well-controlled system, defects in any part of 
pathways involved in the generation of thrombin and production of fibrin can 
cause either thrombotic or haemorrhagic consequences.    
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1.3 MODELS OF HAEMOSTASIS 
1.3.1 Thrombin-based model of haemostasis 
In all reported models of haemostasis to date, the common constant is that 
generation of a stable clot requires a thrombin-mediated conversion of 
fibrinogen to fibrin.  Several in vitro models have been designed, simulating in 
vivo processes and have been used to study the development of a defective clot 
in order to develop therapeutic interventions for bleeding or thrombotic 
tendencies.   
 
1.3.2 Architecture of a fibrin clot 
Currently, mechanisms of fibrin production and clot formation have been 
studied using models that utilise global assays.  These assays differ from clot-
based assays, which although they define coagulation defects,  they do not 
discriminate risks in individuals (Brummel-Zeidins et al, 2003; Brummel-
Zeidins et al, 2005).  Global assays demonstrate the overall pattern of clot 
formation.  Currently, the two commonly used global assays are the 
endogenous thrombin potential (ETP) and thromboelastography (TEG).  These 
assays have been evaluated using clot formation profiles within different 
patient groups and it has been noted that waveform patterns in both ETP and 
TEG show significant correlation between the velocity of the thrombus tensile 






Fibrin formation can be analysed using a turbidimetric assay with the rate of 
clot formation being recorded as shown in Figure 1.2.  The mechanics of the 
fibrin clot being formed have been recently reviewed (Wolberg, 2007).   
 
 Initially, thrombin binds to the fibrinogen molecule, leading to the cleavage of 
fibrinopeptides attached to the E nodule of fibrinogen.  The first strands of 
fibrin that form (protofibrils) are half-staggered and double stranded but the 
clot formed at this stage is not stable enough (the lag phase).  Thicker fibrin 
polymers form and aggregate (lateral aggregation), creating an increase in 
turbidity.    
 
               




The concentration of thrombin present influences the structure of the fibrin clot 






































fibrinopeptides  (Wolberg et al, 2005; Brummel-Zeidins et al, 2005) and allow 
fibrin polymerisation however they produce clots that are turbid and composed 
of thick, loosely-woven fibrin strands (Blomback et al, 1989).  Increased 
concentrations of thrombin produce thinner, tightly-packed fibres which may 
indicate that clots with thin fibres are architecturally more stable.  The impact 
this has on the stability of fibrin is most noticeable during fibrinolysis.   Fibrin 
binds plasminogen and tissue plasminogen activator (tpa) to convert the 
enzyme plasmin that initiates fibrinolysis.  Gabriel and his group showed that 
clots with thicker fibres had an advantageous susceptibility to lysis (Gabriel et 
al, 1992).  Thinner fibres have a slower rate of tpa-mediated lysis which means 
that these clots were more resistant to fibrinolysis.  When observed at a fibrin 
monomer level, it was revealed that thicker fibres lysed slower individually.  
The increased lysis rate noted during polymer fibrinolysis was attributed to the 
fact that clots formed in the presence of low thrombin concentrations were 
made up of fewer fibrin strands despite sufficient levels of fibrinogen and 
therefore had a high surface area for plasmin binding.  This suggests that even 
though plasmin is formed on monomer fibrin fibres, its activity through the 
fibrin mesh is rate limited.   
 
1.3.3 Cellular interactions in thrombin generation  
Specific cellular surfaces are required in the coagulation process for the 
purpose of binding zymogens, cofactors and eventually complexes.  All these 
processes occur sequentially in three main stages as described in Section 1.4 
according to the new cell-based model of haemostasis.    
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Initiation of coagulation produces minute concentrations of thrombin, mainly 
due to FXa.  Thrombin levels produced during initiation were found to be in 
the ranges of 0.5 – 2nM which are sufficient for the rapid activation of 
platelets, FV, FXIII and fibrin formation, all of which occur before propagation 
(Brummel et al, 2002; Mann et al, 2006).  It was found that after clotting was 
started platelet activation followed by FXIII and FV activation was observed at 
a clot time of 4 minutes and all this activation precedes fibrinopeptides release.  
After the 4-minute clot time, 25-50% of procoagulant substrates were cleaved 
and 60% of the platelets were activated.  All of this occurred with less than 1% 
of the total thrombin produced.  In conclusion, by the time a clot is visually 
seen, 25%-60% of reactions involved in the formation of that clot will already 
have occurred but 96% of the thrombin will yet to be generated.  Why 
thrombin needs to be produced abundantly after this point is as yet not known. 
 
TF is expressed either by damage after endothelial cell damage or cytokine-
related exposure, although this is still controversial, and its binding to FVII in 
plasma initiates coagulation.    There are three main ways TF is expressed all 
which have stimulated a debate on which of these TF sources plays the major 
role in clot formation.  TF has been reported to be expressed on blood cells, 
contained within circulating microparticles and in a soluble form circulating in 
blood (Orfeo et al, 2005).  These three sources raise the question as to whether 
TF-dependent thrombin generation requires a continuous exposure to TF.  This 
question was answered by Orfeo and his group (Orfeo 2005), first, by 
explaining that functional TF was essential to trigger thrombin production but 
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not required for normal thrombin generation once the reactions had been 
underway for more than 120 seconds.  Next, they concluded that there was no 
active TF in healthy individuals and that a reservoir for TF was unnecessary to 
sustain coagulation.  The clot formed during initiation requires a re-supply of 
blood, not for more TF, but to immediately renew the consumption of 
prothrombin.  In vivo, vasculature is an open system where a resupply of factor 
and platelets is quite crucial and it is this resupply that governs the extent of the 
clot formation reaction.  Ultimately, the phase of thrombin generation during 
initiation is brief and because this TF-induced thrombin generation stage 
happens during an inert stage, it requires re-supply not re-initiation.  During 
amplification, the FXa from the initiation stage produces a small amount of 
thrombin that activates intrinsic co-factors (FVIII, V) and platelets which 
exposes phosphatidylserine (PS) and binding sites for other zymogens.  
Propagation occurs on the surface of activated platelets, employing more 
intrinsic factors and creating a thrombin burst. This thrombin generates a stable 
clot and activates FXIII, which along with Tissue factor fibrinolysis inhibitor 
(TAFI) protects the clot from lysis.  The result is a cross-linked network of 
fibrin polymers with increased elasticity and overall vascoelastic properties.  
The thrombin-based coagulation process follows a graphical dynamic pattern 
(Figure 1.3) when considering the concentration of thrombin generated over 
the course of the process.  This graphical representation has been based on in 
situ (Wolberg, 2007) and in vitro studies (Al dieri et al, 2002; Hemker et al, 
2004; Dargaud et al, 2005; Hemker et al, 2006; Wolberg, 2007), whereby a 
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system was designed to incorporate plasma procoagulants, inhibitors, platelets 
and TF-bearing cells. 
 
Clot formation can therefore be paralleled to thrombin generation as shown in 
Figure 1.3.  The lag phase (T1) lasts for 2-6 minutes with little thrombin 
produced on TF-bearing cells but this can still activate FV, FVIII and platelets.  
The maximum rate (T2) is the propagation phase which lasts for around 10 
minutes and the increasing rate corresponds to the “burst” of thrombin 
production on the activated platelet surfaces.  This is followed by the 
maximum thrombin peak (T3) at which the thrombin-antithrombin (TAT) 
complexes start to reach equilibrium and the amount of measurable thrombin is 
stabilised.  Subsequently, the production of thrombin ends returning the levels 
to baseline as a result of TAT formation.  The lag phase (C1) represents the 
initial stage of thrombin generation (initiation and amplification) on the TF-
bearing cell, platelet activation (explaining the decrease in turbidity), thrombin 
production on platelets and protofibril formation.  (C2) occurs during the 





Figure 1.3 Thrombin generation (Blue) and fibrin clot formation (Black).  During the 
generation of thrombin, there are 3 noted phases.  The lag phase (T1), maximum rate 
(T2), maximum thrombin generated (T3) and the total free thrombin produced {area 
under the curve} (T4).  Clot formation can be paralleled to thrombin generation.  In clot 
formation, C1 corresponds to the lag time, lateral aggregation (C2) shows the maximum 
rate of thrombin regenerated at a steady rate.  (Figure acquired from Wolberg, 2007)   
 
Care should be taken when interpreting and comparing data produced from 
thrombin generation assays (Wolberg, 2007).  There are several variables that 
influence fibrin clot formation especially in some systems where cells are 
present.  Calcium, which is required to assemble procoagulant factors, has been 
reported to shorten the initiation of the clotting process and produces thicker 
fibres than when fibrin is produced in its absence.  The presence of 
antithrombin also reduces thrombin levels as it lowers the concentration of free 
thrombin available (Wolberg, 2007).  This will cause prolonged lag times and 
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ticker fibrin fibres. The presence of other proteins (macro-globular proteins) in 
plasma will also influence clotting.   
1.3.4 Cell surfaces and fibrin structure  
The extrinsic and intrinsic pathways play vital roles in the formation of fibrin 
clots.  The extrinsic pathway produces low concentration thrombin on TF-
bearing cell surface that triggers the onset of fibrin clot formation (Wolberg et 
al, 2005).  Initially, it was believed that this early fibrin mesh was more porous 
and that later on when more thrombin was produced, a more tightly packed 
mesh was layered on top of the initial mesh, creating a more condensed and 
therefore secure clot (Blomback et al, 1994).  More recently, it has been 
suggested that after the initial low-thrombin based fibrin clot is formed, the clot 
itself evolves with the addition of new fibrin strands to the already formed 
fibrin mesh.  These subsequent strands elongate and cross-branch other strands 
present, creating a dense fibrin clot.  This indicates that the final fibrin clot 
formed is composed of several different sized fibrin fibres.   
 
In conclusion, the presence of procoagulant factors, cellular counterparts as 
well as thrombin generated during clot formation, all determine the structure 
and subsequently the stability of the clot.   
 
 
1.4 CELL-BASED MODEL OF HAEMOSTASIS 
Initially, the coagulation cascade was considered to be the classical 
representation of the coagulation model.  It was this cascade model that most 
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laboratory tests were based on to evaluate haemostatic disorders.  This earlier 
theory of haemostasis originally indicated that coagulation factors controlled 
haemostasis in a system where cells, particularly platelets, merely provided 
phosphatidylserine-containing surfaces on which these procoagulant proteins 
assembled. 
 
This theory however did not explain haemostatic mechanisms in vivo. In 
particular, why certain groups of patients had a bleeding tendency and also it 
did not predict which patients were at risk of bleeding.  An example of this is 
in patients that are deficient in FXII (factor XII), HMWK (high molecular 
weight kininogen) or prekallikrein.  These patients do not present with a 
bleeding tendency although they show a prolonged APTT (activated partial 
thromboplastin time) on analysis.  The APTT test reveals dysfunctional factor 
activity or level, especially in the intrinsic pathway.  In patients with FXI 
(factor XI) deficiency, there is an increased risk of haemorrhage but the APTT 
is not indicative of the extent to which the patient may bleed even though the 
bleeding is markedly lower than that seen in haemophilia A or B.  The new 
cellular model of haemostasis incorporates the cellular components of 
haemostasis and the role they play in achieving haemostasis.     
 
A cell based model has recently been proposed that highlights the role of 
different cells with similar phosphatidylserine contents and how they are able to 
play different roles in haemostasis (Hoffman, 2003).  The new cell-based model 
proposes explanations for the varying degrees of haemorrhage encountered in 
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the presence of factor deficiencies in both the extrinsic and intrinsic pathways.  It 
explains why even though the extrinsic pathway in haemophiliacs is functional 
there still is pronounced bleeding.  In addition, it explains why the extrinsic 
pathway cannot sustain adequate clot formation to prevent bleeding in 
haemophiliacs.  It acts as a stepping stone to answering some of the questions 
surrounding various other deficiencies in haemostasis and further highlights that 
coagulation occurs in three different stages on three different cell surfaces.  
Initiation occurs on a TF-bearing cell where as in the amplification stage, 
platelets and co-factors assemble to prepare for the large thrombin burst and the 




Figure 1.4 Initiation of coagulation (Figure obtained from www.novonordisk.com) 
Initiation of coagulation (Figure 1.4) occurs when sub-endothelial tissue is 
exposed to the circulation at a site of injury.  The tissue factor expressed in 
endothelial cells is released and binds to endogenously activated FVII to form a 
TF/FVIIa complex.   Therefore a cellular source of TF is essential.  There has 
 
29 
been evidence (Mann, 1992 and Hoffman, 2003) showing that initiation of 
coagulation can occur in the vasculature of healthy individuals.  This is 
because certain factors (FVII, FX and FII) infiltrate tissue spaces, depending 
on their molecular size and are activated by TF.  These factors have been 
detected in lymph and have been assayed along with their activated and 
inactive peptide forms (Mann, 1992).  This may imply that activated factors are 
present at basal states and that thrombin production can take place outside the 
vasculature as demonstrated in healthy subjects ((Mann, 1992)) even when the 
vascular wall in intact.  This indicates that the initiation phase is constantly 
activated contrary to findings of other studies (Orfeo et al, 2002), although in 
order to form a stable clot the link between the vasculature is required. In order 
to generate a clot, approximately 2nM of thrombin is required.  At high 
concentration of TF, the generation of FXa is dominated by the TF/FVIIa 
complex rather than the FVIIIa/FIXa complex, as has been shown in vitro 
(Mann et al, 2006).   
 
There are several sources of TF, which include stromal fibroblasts, 
mononuclear cells, macrophages and endothelial cells but unless vessel injury 
or inflammation occurs, TF does not come in contact with blood. When vessel 
wall injury is present, the TF/FVIIa complex subsequently produces minute 








Figure 1.5 Amplification of coagulation (Figure obtained from www.novonordisk.com) 
 
Under normal circumstances, haemostatic components in the vascular tissue 
cannot escape the endothelial layer because of their size.  However, in the 
presence of vessel wall injury, platelets, FVIII and VWF (von Willebrand 
factor) leave the vascular tissue and come into close proximity with the small 
amount of thrombin generated during initiation.  Platelets adhere to the injury 
site and form a plug on the damaged vessel wall.  A minute level of thrombin 
generated (Figure 1.5) activates these platelets by initiating a conformational 
change through the “flip-flop” mechanism, allowing them to expose their 
phosphatidylserine-rich surface.  This thrombin further activates factor FV 





 1.4.2.1 Priming 
This component of haemostasis shown in Figure 1.6 is based on a cell model, 
derived experimentally, from TF sources such as monocytes and fibroblasts as 
oppose to relipidated TF and also use activated platelets for the generation of 
thrombin (Kjalke, 1998 and Hoffman, 2001).  Priming provides an explanation 
for the recruitment of platelets and the role they play within the clot. 
 
 
Figure 1.6 Priming in coagulation.   
(Figure is derived from Kjalke, 1998 and Hoffman, 2001) 
 
During this stage the TF-generated thrombin produced from the initiation stage 
binds to the platelets that have adhered to the extravascular matrix tissue, 
mediated in part by VWF binding to collagen.  Binding to matrix proteins like 
collagen activates the platelets and localises them at the TF site.  Thrombin 













mechanisms.  One of the well-known PAR agonists is thrombin, which is a 
multifunctional serine protein generated during blood coagulation. Thrombin 
interacts with cells via a specific proteolysis of the extracellular NH2-terminal 
of PARs, which leads to exposure of a new tethered ligand, binding 
intramolecularly to the receptor and initiating signal transduction (Lau et al, 
1994). Two of the four PARs, PAR1 and PAR4, have been identified in human 
platelets and are responsible for thrombin-induced platelet activation (Kahn et 
al, 1999). The dual stimulation via collagen and thrombin results in platelet 
activation higher than that seen with other agonist stimulation.  Thrombin-
derived stimulation allows platelet degranulation and the subsequent release of 
FV from platelet  granules.  Collagen stimulation of the platelet receptors 
results in platelet expressing high levels of FV.  Thrombin cleaves the partially 
activated FV to a fully active form.  The same cleavage process applies during 
the activation of FVIII resulting in its release from its co-factor binding 
molecule von Willebrand factor. 
The flip-flop mechanism in platelet activation exposes phosphatidylserine 
which is required for binding to the -carboxyglutamic acid (Gla) residues of 
the clotting factors in a calcium-dependent manner.  TF-generated thrombin 
binds to specific receptors on platelets to prevent being neutralised by 
antithrombin.  Unactivated platelets have at least 3 binding receptors for 
thrombin that include the GPIb-IX-V complex that binds thrombin at the 
heparin-binding site, PAR1 that binds thrombin through the substrate-binding 
site and anion-binding exocite 1.  After the PAR1 is cleaved by thrombin, a 
new amino terminus with a tethered ligand then binds to other nearby PAR1 
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receptors, triggering a signalling cascade.  PAR4 has shown some signalling 
capabilities but is mainly linked to platelet aggregation rather than platelet 
procoagulant activity, which means that its role in haemostasis occurs much 
earlier during primary haemostasis (Monroe et al, 2002).  The FVIII-VWF 
complex allows FVIII to bind to platelets through the VWF binding site on the 
GPIb-IX-V complex.  This brings FVIII in close proximity to thrombin and 
allows for FVIII activation.  FXI binds reversibly to platelets and this binding 
is enhanced by the presence of prothrombin (Baglia and Walsh, 1998).   
Platelet-binding proteins play a major role in propagation.  FVa binds tightly to 
lipids and acts as a binding protein for FXa on the platelet surface.  FIXa binds 
to platelets in the absence of FVIIIa but this depends on the phosphatidylserine 
content of the lipids (Monroe et al, 2003).  The result of priming is a platelet 









At this stage of coagulation, the TF-generated thrombin will have generated 
several activated proteins that cause a higher concentration of thrombin 
(approximately 1nM) to be generated during the propagation stage (Mann et al, 
2006) as shown in Figure 1.7.  On the surface of activated platelets, FIXa 
combines with its co-factor FVIII and this occurs the moment FIXa reaches the 
platelet surface. The initial FIXa is formed by the TF/FVIIa complex and can 
move to the platelet surface because FIXa is not rapidly inhibited by TFPI, and 
AT only inhibits it at a very slow rate (Hoffman, 2003; Monroe et al, 2006).  
FIXa can also be produced on platelet surfaces by FXIa.  Tenase complex 
activates FX to FXa which immediately combines with FV, forming a more 
protective complex away from TFPI and AT, even in the presence of heparin.  
This Prothrombinase complex converts large amount of prothrombin to 
thrombin, which cleaves f fibrinogen to fibrin monomers that polymerise and 
fuse the platelet plug into a stable clot.  The cell based-based model allows a 
more thorough understanding of how the coagulation system works and 
provides a larger degree of consistency with clinical observations when it 
comes to coagulation disorders.  
 
1.5 COAGULATION ABNORMALITIES IN CRITICALLY 
ILL PATIENTS 
 
There are several predisposing factors and conditions that compromise the haemostatic 
status in critically ill patients, which subsequently may lead to multiple organ failure 
in the absence of therapeutic intervention.  Many of these patients develop 
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abnormalities in haemostasis of variable degrees, from minor ones such as prolonged 
clotting times and isolated thrombocytopaenia to complex ones such as disseminated 
intravascular coagulation (DIC).  There are several underlying causes that may be 
responsible for disturbed coagulation in critically ill patients and they each may 
require specific therapeutic intervention.  Parameters, like prolonged coagulation 
times, reduced levels of coagulation inhibitors, or increased fibrin degradation 
products, all indicate alterations in coagulation that can be easily measured and 
managed specifically.   
 
A large proportion, 35-44%, of critically ill patients suffers thrombocytopaenia with a 
platelet count of under 150x10
9
/L (Vanderschueren et al, 2000; Baughman et al, 1993; 
Strauss et al 2002).  This incidence is higher in surgical or trauma patients where 
approximately 41% of these patients have less than 100x10
9
/L platelets (Stephan et al, 
1999 and Hanes et al, 1999).  The main clinical significance of thrombocytopaenia is 
that it is related to an increased risk of bleeding.  In addition to this, a stable reduction 
in platelet counts is an indication of active coagulation, which in turns contributes to 
microvascular failure and organ dysfunction.  However, regardless of the cause, 
thrombocytopaenia in critically ill patients is an independent predictor of ICU 
mortality (Vanderschueren et al, 2000 and Strauss et al, 2002) in that patients that 
maintain a sustained drop in platelets show a 4- to 6-fold increase in mortality.  The 
severity of thrombocytopaenia in critically ill patients is inversely proportional to the 
survival rate and studies have shown that the platelet count is a stronger indicator of 
ICU mortality than the standard composite scoring systems like the Acute Physiology 
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and Chronic Evaluation (APACHE) II score (Vanderschueren et al, 2000 and Acka et 
al, 2002).   
 
Prolonged clotting times (like the prothrombin time (PT) and activated partial 
thromboplastin time (APTT)) occur in approximately 28% of critically ill patients 
(Chakraverty et al, 1996 and Macleod et al, 2003).  Trauma patients have a high 
incidence of prolonged times and studies have shown that the presence of a prolonged 
PT and/or APTT is a strong independent predictor of mortality (MacLeod et al, 2003).  
Other indicative tests include elevated fibrin degradation products and reduced levels 





Thrombocytopaenia in critically ill patients is caused by different factors.  The most 
common factors include sepsis, DIC, massive blood loss, thrombotic microangiopathy 
and heparin- or immune- or drug-induced thrombocytopaenia.    
a) Sepsis 
Sepsis is the host’s response to infection and this is characterised by the release of 
inflammatory mediators that culminate into a wide range of responses (such as 
hypothermia, increased oxygen consumption, tachycardia, hyperglycaemia and lactic 
acidosis as well as liver and renal function alteration).  In septic patients, the main 
factors that contribute to thrombocytopaenia are impaired platelet production, 
increased consumption or destruction, or platelet sequestration in the spleen.  Even 
though there is a high circulating level of thrombopoietin, there is an impaired 
production of platelets from the bone marrow.  In critically ill patients 
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haemophagocytosis may occur where megakaryocytes and other haemopoetic cells are 
cleared from the bone marrow by monocytes and macrophages in response to the 
macrophage colony stimulating factor (Francois et al, 1997).  Thrombin is the main 
activator of platelets in vivo and thrombin production is a ubiquitous event in sepsis 
even with or without the presence of DIC. 
b) Disseminated Intravascular Coagulation 
Patients with DIC have a low or decreasing platelet count (Levi and ten Cate, 1999).  
However the presence of DIC complicates other underlying conditions such as sepsis, 
trauma or cancer and the impact of DIC in critically ill patients is further discussed in 
section 1.5.3 
c) Thrombotic microangiopathy 
Thrombotic microangiopathy defines a group of syndromes (HUS [haemolytic-uremic 
syndrome], TTP [thrombotic thrombocytopenic purpura], severe malignant 
hypertension  and chemotherapy-induced microangiopathy), which all have a common 
pathogenic denominator that is endothelial damage.  Endothelial damage causes 
platelet adhesion and subsequently aggregation.  The result of this endothelial damage-
induced platelet aggregation is thrombocytopaenia, mechanical fragmentation of red 
cells as they are forced through the clot mesh at high pressure and obstruction of the 
microvasculature of organs such as the brain and kidneys, which leads to renal failure 
and neurological dysfunction.  All of these syndromes have different aetiologies. In 
TTP, it is the absence of von Willebrand cleaving enzyme ADAMTS-13, that leads to 
ultra-large multimers attached to the endothelial cells binding to platelet receptors and 
causing platelet adhesion and aggregation.  In HUS, a cytotoxin released from gram-
negative bacteria causes endothelial cell and platelet activation.   In severe malignant 
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hypertension and chemotherapy-induced microangiopathy, it is the direct mechanical 
stress of the high pressure and the chemical stress that cause the endothelial damage.   
d) Heparin- and drug-induced thrombocytopaenia (HIT and DIT)  
Administration of heparin carries a 5% risk for the development of HIT in patients 
receiving heparin, although this is dependent on dosage and duration of 
administration.   HIT is caused by an antibody binding to heparin platelet factor-4 
complex expressed on the surface of the platelet.  This results in high elevation of 
platelet activation and therefore consumptive thrombocytopaenia.  A small proportion, 
1%, of critically ill patients given heparin will develop HIT (Verma et al, 2003) but 
this is also dependent on whether they are given low molecular weight heparin or 
unfractionated heparin, the later having a higher risk of HIT development.   
DIT may be caused due to drug-induced myelosuppression or as a result of immune-
mediated reactions to the drugs.  DIT is more difficult to diagnose as critically ill 
patients are usually exposed to a myriad of drugs and other causes for 
thrombocytopaenia.  Usually, the diagnosis is based on eliminating other causes, 
calculating when the thrombocytopaenia developed and which drug was introduced at 
the time. 
 
1.5.2 Prolonged global clotting times 
 PT and APTT are global assays but do not thoroughly reflect the in vivo haemostatic 
picture but they conveniently give an estimation of coagulation factors for which 
either the PT or the APTT is sensitive.  Generally, if the factors levels are below the 
lowest reference value for these tests, then the times will be prolonged, but it should 
be noted that the sensitivity of these tests varies markedly depending on the reagents 
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used.  As a result an international normalised ratio (INR) is used by most centres to 
allow greater standardisation between laboratory centres.  This parameter has only 
been validated for control of the intensity of anti vitamin K dependent therapy 
(Kitchen and Preston, 1999).   
a) Impaired synthesis 
In most critically ill patients, factor deficiency is usually due to consumptive 
coagulopathy or impaired synthesis or development of a factor inhibitor as seen in 
acquired haemophilia.  Impaired synthesis is usually due to liver insufficiency or 
vitamin K deficiency.  The PT is sensitive to both conditions and especially sensitive 
to FVII.  FV is not a vitamin K-dependent factor whereas FVII is.  This means that 
FVII deficiency is more indicative of liver failure than FV.  Measurement of both 
these factor levels can be used to identfy the presence of liver impairment. 
b) Consumptive coagulopathy  
Massive blood loss due to trauma or surgery is one of the ways that uncompensated 
factor loss may occur.  This is also the case where massive blood loss has been 
compensated by volume replacement using crystalloids, colloids and red cells units 
without factor replacement.  Trauma patients tend to develop hypothermia, which 
underestimates coagulation in vivo since most of the laboratory tests are standardised 
at 37C.  Factor consumption also occurs in a DIC setting. 
 
1.5.3  Disseminated Intravascular Coagulation 
There are three critical events within DIC. They include thrombin production, the 
mechanism sustaining the production of thrombin and the associated activation of the 
inflammatory cascade.   
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a) Inflammatory link to coagulation 
 
 
Figure 1.8 Activation of coagulation after inflammatory response.  Figure derived from Levi, 2002 
 
DIC occurs frequently as a complication of severe sepsis, trauma and several other 
conditions.  DIC is a condition that is associated with patients in the ICU setting and is 
a result of several haemostatic abnormalities in these patients.  These abnormalities are 
not rare in the ICU setting with a higher incidence in the medical than in the surgical 
setting.  Rate of mortality relates to the platelet count but mortality is dependent on 
bleeding where platelet counts are involved. Bacterial infections are also common in 
patients that need intensive care and so are responsible for the most common 
combination that causes coagulation abnormalities, namely sepsis and DIC.  
Combined sepsis and DIC play a significant role in subsequent depletion of platelets 




Procoagulant and inflammatory response to infection are closely linked.  Infectious 
agents induce the release of inflammatory cytokines such as IL-1, IL-6 and TNF- that 
activate coagulation by simulating TF release from monocytes and damaged 
endothelium.  TF leads to the formation of thrombin and a fibrin clot (Figure 1.8).  
Inflammatory cytokines and thrombin both impair the endogenous fibrinolytic system 
by releasing PAI-1 from platelets and endothelium.  PAI-1 inhibits tissue plasminogen 
activator (tPA), which endogenously lyses fibrin.  This means that the lytic process is 
downregulated.  In addition to this, thrombin itself stimulates TAFI activation which 
prevents clot lysis.  This is vital in microvascular thrombosis.   
 
The inflammatory response also affects the activation of protein C.  Protein C requires 
thrombin-bound thrombomodulin and since the damaged endothelium will result in 
low levels of expressed thrombomodulin, the end result is usually the development of 
diffuse endovascular injury, microvascular thrombosis, organ ischaemia, multiorgan 
dysfunction and possibly death. 
Studies have shown that critically ill patients have a microbiologically confirmed 
infection and these bacterial infections were found to be the most common cause of 
hospital acquired infections, with staphylococci being the most common blood isolates 
and Candida Albicans being the most common pathogen isolated from Urine 
(Foreman et al, 2003 and Osmon et al, 2003).  In lung injury, there is increased 
permeability of the alveolar-capillary membranes, alveolar damage and accumulation 
of pulmonary oedema that contains a high concentration of proteases.  There is also 
extensive epithelial necrosis, swollen endothelial cells with widened intracellular 
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junctions, with fibrin deposits in the hyaline membranes of the alveolar ducts and air 
spaces.  Later stages of lung injury show massive neutrophil and macrophage 
infiltration as well as fibrinous thrombi in the alveolar capillaries and smaller 
pulmonary arteries (Toh and Dennis, 2006).  These studies have helped identify the 
overall impact of infections on patient outcomes, especially hospital mortality 
b) In vivo thrombin generation and its preservation 
Thrombin generated in vivo is controlled by the protein C pathway and several other 
mechanisms that control surface expression and signalling on endothelial cells.  
Although tissue factor and the intrinsic pathway influence thrombin generation, the 
burst of thrombin generated from the intrinsic pathway also results in the consumption 
and depletion of protein C, antithrombin and protein S.  The increased exposure of 
cellular surfaces rich in phosphatidylserine provide externalisation of the inner cell 
surface membrane and induce apoptosis.  Cell damage releases microparticles from 
platelets, monocytes and endothelial cells, all of which increase the availability of 
phosphatidylserine-exposed surfaces on which coagulation reactions occur.  Low 
density lipoprotein is present in sepsis and acts as a negatively charged surface on to 
which coagulation occurs (Toh et al, 2002).   
 
Critically ill patients with DIC have a low and decreasing platelet count, prolonged 
clotting screen, low levels of plasma coagulation factors and/or increased fibrin 
degradation products (Levi et al, 2002).  Therefore, a collection of tests is considered 
when diagnosing DIC i.e. Platelet counts, clotting screen, D-dimer assay and 
fibrinogen level.  These four tests are designed as the DIC score and are used as a 
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strong and independent predictor of mortality in critically ill patients with DIC 
(Dhainut et al, 2004). 
 
1.5.4 Other coagulation defects in critically ill patients 
The tests mentioned above in regards to diagnosing conditions in critically ill patients 
sometimes may not reveal any significant defects, in particular platelet dysfunction or 
even hyper-fibrinolysis.   
Critically ill patients with renal dysfunction or severe liver failure frequently have 
platelet dysfunction and so do patients that are taking anti-platelet drugs such as 
aspirin or patients that are taking non-steroid inflammatory drugs or potent thrombin 
inhibitors (e.g. hirudin).  To date, there is no accurate routine test for platelet function 
in critically ill patients and assay methods such as the platelet function assay, which 
equates to the bleeding time, is imprecise (Forestier et al, 2002).   
 
In patients that have specific types of cancer (e.g. acute promyelocytic leukaemia) 
hyper-fibrinolysis is frequently present, although generally it is not that common in 
critically ill patients.  Patients that are treated with thrombolytic agents will have 
induced hyper-fibrinolysis.  Increased hyper-fibrinolysis is detected through raised 
levels of fibrin degradation products and low fibrinogen levels.  Other indicators 







1.6 RECOMBINANT ACTIVATED FACTOR VII (rFVIIa) 
 1.6.1 Development and Production of rFVIIa 
Recombinant human coagulation Factor VIIa (rFVIIa) improves haemostasis 
by activating the extrinsic pathway of the coagulation cascade.  
 
Like 
endogenous FVIIa, rFVIIa is a vitamin K-dependent glycoprotein consisting of 
406 amino acid residues (MW 50 KDa) that is structurally similar to human 
plasma-derived FVIIa.  NovoSeven is supplied as a sterile, white lyophilized 
powder of rFVIIa in single-use vials.  It is a delipidated protein that requires a 
phospholipids surface such as that provided by activated platelets and damaged 
endothelial cells.   
The liver is the primary site of FVII synthesis in humans. The production, 
therefore, of recombinant human FVIIa requires a mammalian expression 
system so that a protein with the necessary post-translational modifications, 
such as γ-carboxylation and glycosylation, can be produced.  Using a 
mammalian cell system derived from hamster kidney cells, rFVIIa is produced 
in large amounts.  It is produced as a single chain that is spontaneously 
activated during processing, at the purification stage (Jurlander et al, 2001).   
The amino acid sequence and posttranslational modifications of rFVIIa from 
the cell line were compared to human plasma FVIIa and found to be identical, 
with regard to the primary structure, for the amino acids sequence and identical 
to that predicted from the cDNA sequence.  In rFVIIa, nine of the ten Gla 
residues are fully -carboxylated and one partially -carboxylated and the two 
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O-glycosylated sites are similar but the O-linked structures differed slightly 
between the plasma-derived FVIIa and the recombinant form.  Quantitatively, 
the carbohydrate composition is different in that rFVIIa has a higher fucose 
content and lower sialic acid content than plasma-derived FVIIa (Thim et al, 
1988).  The low sialic acid content of the recombinant protein may explain the 
properties of rFVIIa since sialic acid is mainly found on glycolipids where its 
presence is responsible for the negative charge on the surface of animal cells.  
However, the low sialic acid content in rFVIIa explains the delipidated 
properties of the protein and why it requires a negatively charged surface to 
bind TF and FX.    
1.6.2 Introduction of rFVIIa use in coagulopathies 
Severe haemophiliacs require prophylactic therapy with a haemostatically 
effective treatment to avoid chronic anthropathy development as a result of 
regular joint bleeds.  This treatment is also used if patients suffer trauma or 
surgical-related bleeds.  Approximately, 20% of severe haemophiliacs develop 
an antibody against the factor that they lack and prophylactic replacement of 
the deficient factor may not be as effective as the factor is neutralised by the 
existing antibody. Much research has focussed on finding therapies that target 
mechanisms that bypass the FVIII/FIX factors, which deficient in haemophilia 
A and B patients.  APCCs (Activated Prothrombin Complex Concentrates) 
contain both activated factors and their zymogens and are still widely used as 
FVIII bypassing agents, but they only give 50-65% effective responses in the 
patients (Sjamsoedin et al, 1981; Lusher et al, 1983) with some 
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thromboemobolic events reported (Lusher, 1991).   After Hedner and his co-
workers looked at canine models to identify the factors most involved in the 
development of these side effects, they concluded that FVII/FVIIa was a useful 
haemostatic candidate that utilises a pathway independent of FVIII/FIX 
(Hedner et al, 1979).  Further work by this group demonstrated that purified 
plasma-derived FVIIa induced haemostasis in severe haemophiliacs through 
therapeutic physiological levels of FVIIa binding TF and activating FX at the 
site of injury (Hedner and Kisiel, 1983).   rFVIIa has since been used to 
enhance coagulation in haemophiliacs with inhibitors and is now being used in 
other coagulopathy conditions besides haemophilia.   
1.6.3 Pre-clinical development 
The haemophilic canine models that were used to test the hypothesis that 
rFVIIa can be effectively used in circulation showed an appropriate 
physiological response to these rFVIIa dosage without any systemic activation 
of haemostasis after the administration (Brinkhous et al, 1989).  This was 
based on several hypothetical factors.  Firstly, no specific inhibitors to FVII 
have been identified and so it should not be cleared so readily from circulation.  
Secondly, in the absence of TF, the rFVIIa will be inactive in circulation.  The 
third point is that at the injury site, TF is generated as a cell-membrane receptor 
for FVIIa and the TF/FVIIa complex forms promptly to initiate the extrinsic 
pathway, which indicates that TF may be essential for rFVIIa to work.  Lastly, 
the extrinsic pathway in haemophilia is normal.  Consequently, the 
administration of rFVIIa in haemophilia could allow for the generation of 
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sufficient thrombin and platelet activation to facilitate the formation of a stable 
plug.  A comparative study that was conducted in rabbits showed that FEIBA 
(Factor Eight Inhibitor By-passing Activity) significantly lowered the platelet 
counts and fibrinogen while increasing the APTT, demonstrating an overall 
consumption of coagulation factors (Diness et al, 1992).  This was not the 
effect found with rFVIIa. 
VWD homozygous type I or type III canine models did not show any 
improvement in haemostasis even at higher doses indicating the importance of 
a platelet adhesion and aggregation for the full action of rFVIIa (Brinkhous et 
al, 1989; Roberts et al, 2004).  The defect in these models was severe and was 
primarily attributed to defective platelet adhesion and agglutination resulting 
from the absence of VWF.   
1.6.4 Clinical development 
It was during an open surgical synovectomy in 1988 that the first severe 
haemophiliac was treated with rFVIIa without any complications or peri- or 
postoperative abnormal bleeding.  After this, an efficacy rate of 90-100% was 
confirmed in relation to several severe haemophiliac patients undergoing major 
surgery (Ingerslev et al, 1996 and Shapiro et al, 1998). Other reviews have 
reported efficacy rates in limb- and life-threatening bleeds to be between 76%-
84% in severe haemophliacs with inhibitors (Lusher et al, 1998; Abshire and 
Kenet, 2004 (a); Lusher et al, 1998 and Key et al, 1998).  rFVIIa was approved 




1.7 TREATMENT AREAS: CONGENITAL AND 
ACQUIRED HAEMOPHILIA 
  1.7.1  Haemostasis in haemophiliac patients 
Congenital haemophilia A and B is inherited in an X-linked recessive manner 
and is defined by the reduction or the absence of FVIII, FIX respectively 
(Haemophilia C is inherited in an autosomal recessive manner and is 
characterised by a reduction or absence of FXI).  The lack of these factors 
results in inefficient activation of FX on the platelet surface and so there is no 
amplification stage of coagulation (Figure 1.5).  Over the larger part of the 20
th
 
century, haemophiliacs were managed with replacement therapy of the 
deficient factor from products derived from donor human blood products.  
Some of these patients developed antibodies to the replacement factors, which 
is why the development of rFVIIa has proved vital in these patients.   
Acquired haemophilia is a spontaneous autoimmune disorder where patients 
with previously normal haemostasis develop IgG auto-antibodies directed 
against clotting factors.  Most antibodies develop against FVIII, but FIX auto-
antibodies are less common.  Development of antibodies against other clotting 
factors is even rarer.  Part of the treatment includes immunosuppressants and 
treatment with factor replacement, rFVIIa and activated prothrombin complex 
concentrate (e.g FEIBA).   
 
1.7.2  Rationale behind bleeding in haemophilia 
 The cell-based model gives a better understanding of the pathophysiological 
responses observed in haemophiliacs.  With the classic coagulation cascade 
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model (i.e. the non cell-based model), the indication is that the TF pathway 
does not produce sufficient FX to sustain haemostasis since in haemophiliacs 
there is less or no FXI and FVIII to activate.  The FX generated at the Tenase 
complex is not sufficient for the thrombin burst observed during amplification.  
The reason for the insufficient FX production is accounted for when the cell-
based model is applied.   
 
The explanation given by the cell-based model (based on Hoffman, 2003) isn’t 
that the TF-generated FXa is insufficient but rather that it occurs on the wrong 
cell surface.  The FIXa/FVIIIa complex activates FX on the platelet surface 
during propagation and the TF/FVIIa activates FX on the TF-bearing cell.  FXa 
produced on the TF-bearing cell cannot move to the activated platelets because 
it is liable to inhibition by two major plasma FXa inhibitors (AT and TFPI).  
During circulation, both TFPI and AT inhibit FXa so rapidly and effectively 
that the half-life of this protein is 1 minute or less in the fluid phase.  FXa that 
remains at the TF-bearing cell is protected from inhibition, where as any FXa 
that diffuses from this cell surface is quickly inhibited.   
 
This would suggest that haemophilia is a result of failure of platelet-surface 
activation of FX, i.e. a lack of platelet-surface thrombin production.  The 
initiation and amplification stages of coagulation are relatively normal which 
means that they can form the initial platelet plug but cannot generate a 
thrombin burst at the platelet surface that is necessary to stabilise this initial 
plug.   
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1.7.3 Use of rFVIIa in haemophiliac patients 
Replacement therapeutic responses have proven useful in the management of 
congenital haemophilia.  However, alloantibodies to these products in some 
patients created somewhat of a challenge initially, before the development of 
FVIII/FIX bypassing agents.   Recombinant FVIIa has a structural homology to 
endogenous plasma-derived FVIIa.  rFVIIa use was first investigated 
experimentally using plasma-derived FVIIa as treatment in haemophiliacs with 
inhibitors (Hedner et al, 1989) but now rFVIIa has been indicated for the 
treatment of patients with acquired haemophilia A and B with an efficacy of 
90-95% (Von Depka, 2002, Von Depka 2005).  The efficacy of this drug is not 
determined by the inhibitor levels and unlike plasma-derived products, it does 
not cause a renewed rapid antibody production on the second (or subsequent) 
encounter.  Several case studies and reports have shown that rFVIIa use is 
useful in individuals without any pre-existing coagulopathies; as those seen in 
patients with acquired haemophilia (Hedner, 2002).  Recombinant FVIIa 
induces haemostasis independent of FVIII or FIX in patients with acquired 
haemophilia as studies have shown (Lusher et al, 1998; Hedner and Ingerslev, 
1999).  The standard recommended dose is 90-120g kg
-1
 given every two 
hour with increasing dose intervals, depending on the clinical outcome of the 
patient (Hedner and Ingerslev, 1998; Lusher et al, 1998; Roberts et al, 2004; 
Von Depka, 2005).  Most plasma proteins have a short half-life and the same 
applies to rFVIIa.  The half-life differs depending on whether the patient is a 
child (3-15 yrs) or an adult (18-55 yrs) as indicated in a pharmacokinetics 
study (Villar et al, 2004) and a case report (Cooper et al, 2001).  The T1/2 was 
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reported at an average value of 1.32hours (1.27-1.40hours) in children and 2.72 
hours in adults (Cooper et al, 2001).  The high clearance rates noted in patients 
indicates that a higher does of rFVIIa is required to generate the amount of 
thrombin required to compensate for the lack of FVIII/FIX in haemophilia.   
 
Inhibitor development has been reported to occur in early childhood (9-36 
exposure days) which is why it is vital to investigate inhibitor development in 
children (Villar et al, 2004).  There is literature on the response of adult 
haemophiliac patients to rFVIIa but not to the same extent in children.  There 
have only been two groups that have investigated the pharmacokinetics of 
rFVIIa in children (Hedner et al, 1998 and Santagostino et al, 2001) and both 
have shown a faster clearance of the drug in children than adults.  This high 
level of clearance was attributed to extracellular and total body water spaces 
being relatively larger in children than in adults (Villar et al, 2004).   
 
 Monroe et al, 1997 and Khalke et al, 1998 showed that rFVIIa concentrations 
of 5nmol L
-1 
or higher bound to surfaces of activated platelets and that a 
concentration range of 50-150nmol L
-1 
produced thrombin comparable to that 
seen in controls and at a similar rate.  This is essential for a tight fibrin plug to 
be formed and so the dose of rFVIIa given to these patients is crucial.   An 
improved clinical response with only one single infusion has been reported and 
may require a higher dose in some patients (Abshire and Kenet, 2004 (a)), as 
doses as high as 320g kg
-1 
have been administered to achieve an improved 
clinical outcome.   
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Recent reviews within surgical literature on the use of rFVIIa for life-
threatening bleeding have shown that there are thromboembolic complications 
associated with rFVIIa administration (Warren et al, 2007 (a); Warren et al, 
2008 (b) and Despotis et al, 2008).  A recent paper reported from a review, of 
various medical disciplines, carried out by the Food and Drug administration 
that 1 in 50 patients administered with rFVIIa for an unlicensed indication 
developed a thromboembolic complication and that 1 in 200 patients died (Gill 
et al, 2009).  In cardiac surgery, of the patients that were unresponsive to 
standard transfusion products and were administered with rFVIIa, 19-40% 
suffered mortality and complication as a result of using rFVIIa (Gill et al, 
2009).  These reviews have shown that despite the effectiveness of this drug, 
there are risks associated with it.  This further highlights the need for well-
organised randomised controlled trials to set up effective guidelines.   
 
1.7.4 High-dose rFVIIa use in haemophilia 
The first report of a “mega dose” of rFVIIa was first reported in 1994 in a boy 
with haemophilia B and high-titre inhibitors (Cooper et al, 2001).  Several 
studies have been conducted to investigate high-dose rFVIIa, especially with 
regard to thrombotic implications.  These studies have shown that “mega 
dosing” in rFVIIa use provides a large degree of haemostatic efficacy in 
patients that lack response to standard doses and that it also allows a dosing 
flexibility that is specific to the patient and related to the likelihood of bleeding 
(Abshire and Kennet, 2004 (a); Kenet et al, 2003).  Although mega doses have 
proven successful in paediatric patients, it has been recommended that the 
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standard dose of 90g/kg every 2-3 hours should be maintained in adult 
patients until safety data has been collected (Abshire, 2004 (b)).    Further 
support for high dosing has been reported in cases where doses as large as 
352g/kg (haemophilia B) and 246 and 986g/kg (on five consecutive days for 
haemophiliac A patient) did not show any subsequent increased thrombotic 
potential (NovoSeven prescribing information) although recent literature has 
shown that there is a thromboembolic risk associated with rFVIIa (Warren et 
al, 2007(a) and Despotis et al, 2008). 
 
1.7.5 Mode of action of standard and high-dose rFVIIa 
If patients do not have a pre-existing coagulopathy then rFVIIa will not have 
any effect on the circulatory levels of platelets or fibrinogen but it will increase 
fragment 1 + 2 and Thrombin-Antithrombin (TAT) complexes (Friederich et 
al, 2003).  This is attributed to the diffusion of rFVIIa into the extravascular 
spaces at the site of vessel wall damage where it binds TF and increases F1 and 
F2 levels.  This allows TF to initiate coagulation at the site and enhance 
thrombin production.  Furthermore, rFVIIa is localised at the injury site and 
through TF-independent binding to activated platelets that adhere through von 
Willebrand factor.  If high levels of rFVIIa are present, then factors X and IX 
can be activated on the surface of these activated platelets (WIlbourn et al, 
2003).  Hoffman, 2003 also explains that rFVIIa in vivo undergoes weak 
association with activated platelets especially at high doses; it is not TF-
dependent but rather platelet dependent.  The TF-dependent theory explains 
why rFVIIa is localised at the injury site and for these reasons it may not have 
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any thrombotic implications but it does not explain the need for high doses.  by 
The weak association of rFVIIa in the TF-independent mechanism is improved 
by high doses of rFVIIa.  If TF-independent binding is of a weak affinity, then 
high level doses are required to produce effective haemostasis.  It should be 
mentioned that this TF-independent mechanism does not substitute the TF-
dependent mechanism.  TF is still required to initiate coagulation.  
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 1.8 OTHER TREATMENT AREAS  
1.8.1 FVII deficiency 
Historically, FVII deficiency was treated with APCCs or plasma-derived FVII 
concentrates.  A study was conducted where 17 FVII deficient patients were 
given rFVIIa after spontaneous bleeding episodes, major and minor surgical 
procedures.  Haemostasis was secured in the surgical procedures as well as the 
bleeding episodes and the only side effect was the development of an inhibitor 
against rFVIIa in one patient (Mariani et al, 1999; Scharrer, 1999).  This study 
showed that rFVIIa has efficacy in FVII-deficient patients.  It is also safe since 
any risk of viral transmission is eliminated in its production. 
 
 1.8.2 Congenital thrombocytopaenias 
Congenital platelet dysfunction disorders are a group of rare disorders that 
include two that are characterised by the lack of glycoprotein complexes 
(GPIIb/IIIa in Glanzmann thrombasthenia and GPIb/IX in Bernard-Soulier 
syndrome).  These individuals have a severe mucocutaneous bleeding diathesis 
and have historically required platelet transfusions to correct their haemostasis.   
There are several complications related to this treatment such as transfusion 
reactions and antibody development to missing glycoproteins as well as 
transfusion-related infections from the blood products.   
 
The first case report of rFVIIa use in a severe epistaxis in a boy was first 
reported in 1996 (Poon et al, 1999) and since then additional cases where 
rFVIIa has been used in bleeding and surgical prophylaxis in patients with 
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platelet disorders have been reported (Gerotziafas et al, 2004; Almeida et al, 
2003; He et al, 2005; Galan et al, 2003; Goodnough, 2004). The exact 
mechanism of how rFVIIa works in platelet dysfunction disorders remiains 
unclear but the current proposal is that rFVIIa increased thrombin generation 
on the platelet surfaces by direct activation of FIX and FX and a positive 
feedback mechanism activates the platelets while compensating for the 
qualitative and quantitative defects (WIlbourn et al, 2003; Almeida et al, 
2003).   
 
Several report have shown that rFVIIa at high doses activates FX and FIX on 
the surface of platelets by a TF-independent mechanism (Monroe et al, 1998 
and Hoffman et al, 1998) which explains how rFVIIa normalises haemostasis 
in haemophilia.  Butenas et al, 2002 published data indicating that TF was 
absolutely essential for coagulation activation by rFVIIa but it was later 
clarified that these conflicting data differed as a result of different 
methodologies (Hoffman et al, 2002) although both views carry great 




1.9 GLOBAL ASSAYS IN HAEMOSTASIS 
In order to diagnose a coagulation disorder, an understanding of the clinical 
manifestations as well as a thorough haemostatic investigation is required to 
come to an accurate diagnosis.  Various standard assays within the laboratory 
give a specific biochemical diagnosis but this does not mean that the outcome 
correlates with the clinical phenotype of the individual.  An ideal laboratory 
test would be one that can determine the clinical implication of the biochemical 
diagnosis.  This test should also be useful in monitoring the procoagulant as 
well as the anticoagulant effects of therapy administered.  However, there is no 
current laboratory test that can reflect the overall in vivo haemostatic profile of 
an individual because the development of such an assay is not feasible.  
However, laboratories have employed assays with the potential to highlight and 
correlate both clinical phenotype and clinical efficacy of most haemostatic 
treatments.   
 
  1.9.1 Clotting screens  
Currently, several analysers have been developed that rely on the principle of 
using photometric signalling to assess clot formation.  Using the multi-
disciplinary analyser as an example, results from this device are represented 
graphically, showing an optical profile of light transmittance waveform as a 
function of time defined as a clot waveform.  APTT (Activated partial 
thromboplastin time) waveform analysis has proven beneficial in defining the 
severity of haemophilia when compared to the one-stage factor assay or the 
clotting APTT assay (Shima et al, 2002).  The usefulness of this assay has also 
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been reported in monitoring haemostatic effects in haemophiliac patients given 
rFVIIa (Shima, 2004). 
 
  1.9.2 Thromboelastography/Thromboelastometry 
Thromboelastometry is based on Thromboelastography.  It is an alternative 
version of the classical assay developed by Hartet in 1948.  Both the 
thromboelastograph and thromboelastogram are used to measure elasticity of 
blood by continual graphic representation of the firmness of a blood or fibrin 
clot during its formation and subsequently fibrinolysis.  Since 1996, the term 
TEG has been used to describe the assay performed using the Haemoscope 
device (IL, USA) and alternatively, the device marketed by Pentapharm (Basel, 
Switzeland) uses the term thromboelastometry for the measurement process 
and ROTEM for the device and traces (Luddington, 2005).  The descriptive 
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Table 1.1 Terminology used for TEG and ROTEM parameters Information derived from 
Luddington, 2005 and ROTEM manual, Pentapharm GmbH, 2002/2005 
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This assay provides information about the initiation and propagation kinetics, 
fibrin/platelet interactions, the stability of the clot in regards to how firm the 
clot is and its susceptibility to lysis.  This has been well established in fields 
such as hepatobiliary and cardiac surgery, obstetrics, and trauma medicine and 
also to identify bleeding risk post-operatively (Kang et al, 1985; Tuman et al, 
1987; Kang et al, 1987; Speiss et al, 1995; Kaufmann et al, 1997).  Currently, 
the main use of the TEG is to monitor blood component therapy during surgery 
(Luddington et al, 2005).  This highlights the development this device has 
undergone since when it was first used as bedside monitor for whole blood.     
 
The TEG offers the possibility of bedside testing, giving a result within 30 
minutes regarding the function of platelets, plasma procoagulant and 
anticoagulant ability and the nature of clot lysis.  This gives an indication of 
which blood components need to be administered.  Hence, if the clotting time 
is prolonged, this may indicate fresh frozen plasma as a therapeutic option.  
The strength of the clot is largely influenced by platelet function and 
fibrinolysis may indicate the need for anti-fibrinolytic intervention e.g. 
tranexamic acid use, if accelerated.   Recently, an audit showed that the TEG 
demonstrates a much faster availability of results and a reduced requirement of 
blood products when compared with coagulation laboratory assays, especially 
when looking at peri-operative bleeding (Anderson et al, 2003).  The main 
setback with this assay as a diagnostic tool in laboratories is the lack of 
agreement with standard laboratory variables (Zuckerman et al, 1981).  In 
addition, citrated blood is required within a laboratory setting.  Comparatively, 
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native whole blood and citrated blood parameters differ and this has been 
attributed to incomplete inhibition of activation of the coagulation cascade 
(Zambruni et al, 2004).  It is therefore vital to interpret TEG parameter results 
with a knowledge of sample conditions. 
Within the laboratory setting, this assay has been used to assess clinical 
conditions that other conventional coagulation assays could not adequately test 
for, such as hypercoagulability and thrombosis risk (O’Donnell et al, 2004) as 
well as haemophilia and its response to rFVIIa and APCCs (Hayashi et al, 
2004; Sorensen and ingerslev, 2004) 
 
1.9.2.1 Measurement principle 
The TEG or ROTEM define various parameters that portray the dynamics and 
size of the clot during clot formation and lysis (Figure 1.8).  The sample is 
incubated at 37C in a heated cup and inside the cup, a suspended pin 
connected to a detector system is immersed in the sample.  This is a torsion 
wire in the TEG and an optical detector in the ROTEM.  The pin and cup 
oscillate alternately to each other through an angle of 4.75.  The movement is 
instigated from either the cup in the TEG system or the pin in the ROTEM 
system.  As the clot forms, the transmitted rotation between the cup and pin 
(TEG) or the impedance of the rotation of the pin (ROTEM) is detected and a 




Figure 1.9 Main parameters of the TEG (r, k, and MA)  or ROTEM (CT, CFT, and 
MCF).  Figure adapted from Luddington, 2005 
 
Thromboelastography/thromboelastometry has demonstrated that in certain 
pathological conditions, distinctive traces are generated.  These are shown in 




Figure 1.10 illustration of normal trace and abnormal traces generated during 
thromboelastography/thromboelastometry (adapted from Luddington, 2005) 
 
1.9.2.2 Standardisation of the TEG assay 
Lang and co-workers recently conducted comparison studies on reference 
ranges in this assay between centres (Lang et al, 2005).  Previously, variability 
in results was a result of instrument performance and sample handling. Recent 
advances in technology and novel reagents have improved this greatly.  Lang 
and his group showed that reagent-supported thromboelastography is 
reproducible and that the reference ranges were consistent between centres.  
This means that there can be standard ranges used in this assay for clinical use.  
Standardising the assay begins with standard reference ranges derived from 
 Normal Trace 
Hypercoagulability 
shortened r/CT time 
raised angle and k/CFT 
Hyperfibrinolysis 
prolonged r/CT 








within each centre.  Intra-centre reference ranges have been influenced by 
several factors such as citrate anticoagulants.  This is because analysis of these 
samples is influenced by incomplete inhibition of the activation the cascade 
(Zambruni et al, 2004).  The sample is usually rested for 30 minutes before it is 
analysed and as long as all the tests are performed in a standardised manner 
and processed in the same way, then reference ranges are appropriate for result 
assessment (Luddington et al, 2005). 
 
One of the current modifications to the TEG assay is the use of low 
concentration TF to initiate coagulation.  This technique has been applied to 
monitoring therapy such as that with rFVIIa (Sorensen et al, 2003 (a); 
Sorensen and Ingerslev, 2004 (b)).  In addition to this, analysis of data derived 
from this application was also described where a velocity profile (maximum 
velocity, time to maximum velocity and area under the first derivative curve) 
was calculated from the 1
st
 derivative parameters.  All these new parameters 
have been applied in therapy response analysis (Sorensen et al, 2003; Sorensen 
and Ingerslev, 2004: Sorensen and Ingerslev, 2005).   This application has 
extended to other global assays such as thrombin generation (Luddington and 
Baglin, 2004). 
 
1.9.2.3 Evaluation of TEG against laboratory screening tests 
Laboratory screening tests, such as plasma factor assays, provide an indication 
for a specific area of haemostasis like FVIII deficiency in haemophilia A.  
However, assays such as the TEG have further helped elucidate some factors 
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(such as platelets and plasma content) that affect the outcome and therefore 
interpretation of the result. 
Reports have shown that correlations between TEG variables with laboratory 
screening assays such as MA and the fibrinogen concentration as well as 
platelet count in the normal controls and hypercoagulable individuals exist 
(Luddington, 2005).  Other parameters include the APTT with the r/CT 
parameter and the lysis time with the euglobulin clot lysis time.   
 
The TEG has played a role in the use of blood replacement products especially 
during and post hepatic and cardiac surgery.  It has the ability to simulate 
haemostasis, a factor that has been adapted in order to improve and expand on 
the application of the assay.  In the laboratory setting, anticoagulated samples 
are required for testing indicating a need for stricter interpretation of results.  
Currently, the TEG as a haemostatic reference has proved beneficial but there 
are still areas of improvement such as standardisation and optimisation of 
reagents used in the assay. 
 
1.9.3 Calibrated Automated Thrombography 
This method was developed by Hemker in 1986 based on the assumption that 
thrombin generated in tested plasma or whole blood was an accurate 
representation of the total combination of activities and concentrations of 
procoagulants and their anticoagulants.  Simply, thrombin generation is 
measured after the addition of TF, phospholipids and calcium, when testing 
plasma, at fixed time intervals in a solution that contains a chromogenic 
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substrate.  The rate of thrombin generation is displayed on a thrombin 
generation curve from which additional parameters may be calculated such as 
the lag time, peak height, time to peak and the area under the curve – 
Endogenous thrombin potential (ETP).  The method has been modified over 
the years whereby, initially, a chromogenic substrate with slow reactivity can 
be used which allows for the release of para-nitroaniline by thrombin.  
Recently, fluorogenic substrates have been introduced to replace chromogenic 
substrates (Hemker, et al, 2000).  With this, the fluorogenic signal is not 
disturbed by the turbidity from fibrin formation.  This allowed plasma to be 
tested without defibrination as defibrination was required previously to 
maintain the transparency of the sample. This also meant that responses to 
therapy such as that with rFVIIa could be investigated in platelet rich plasma 
systems (Wegert et al, 2005).  Results from this assay are still dependent on 
several variables such as TF concentration and phospholipids used to initiate 
the reaction.  This assay has been noted to be useful in detecting deficiencies in 
factor deficiencies (FV, FVII, FVIII, FIX and FX) in platelet poor plasma but 
this assay can be used to monitor response to rFVIIa therapy in haemophilia.  
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1.10 RESEARCH AIM 
Critically ill patients present a breakdown of their haemostatic balance that may 
eventually lead to multiple organ failure, without therapeutic intervention.  There are 
several abnormalities in haemostasis of varying degree that develop in these patients, 
ranging from minor ones such as prolonged clotting times and isolated 
thrombocytopaenia to complex ones such as disseminated intravascular coagulation 
(DIC).  There are several underlying causes that may be responsible for disturbed 
coagulation in critically ill patients, all which require specific therapeutic 
intervention.   
 
This research project was designed as a preliminary study for analyses employing the 
use of global assays to analyse clotting in samples taken from ICU patients.  The 
aims were to analyse the clotting profiles in samples taken from ICU patients with 
variable predisposing illnesses.  Analysis was to be carried out on both whole blood 
and plasma samples using the thromboelastography (TEG) assay to analyse clotting 
status and the use the modified CLoFAL assay to analyse the rate of clot lysis.   
Clinical information on these patients was withheld and the samples anonymised to 
prevent bias in interpretation of the results obtained.  These patients had been 
admitted to the ICU ward for over 1 week and therefore were considered to be very 
ill.  Samples from two control groups were also used in the project, haemophiliac 
samples and samples taken from healthy individuals.  Haemophiliac samples were 
taken at baseline level or in cases where the individual had factor concentrate 
administered, samples were taken 4 days after the administration of the last dose.  
Not only were the control groups used comparatively for the preliminary biochemical 
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analysis, but they were also used in analyses for sample responses to the pro-
coagulant agent, activated recombinant FVII (chapter 3). 
 
Before TEG and CLoFAL assay analysis was commenced, preliminary 
investigations were conducted to determine any biochemical alterations in 
coagulation in the ICU samples.  This was carried out for each sample that was 
collected from the ICU patients.  Alterations in coagulation were measured through 
parameters such as platelet counts, coagulation times, factor levels and fibrin 
degradation products.  These data are shown in Section 3.2 and is discussed in 
Chapter 4.   
 
Changes in coagulation can be measured by assaying parameters such as prolonged 
coagulation times, reduced levels of coagulation inhibitors, or increased fibrin 
degradation products.  However, these are standard assays used within the laboratory 
to give a specified biochemical diagnosis but their outcome may not correlate with 
the clinical phenotype of the individual.  Global assays are a benchmark for 
monitoring both pro-coagulant and anti-coagulant effects on haemostasis, be it from 
administered therapy or in vivo alterations.  To date there is no assay that reflects the 
overall in vivo haemostatic profile.  Global assays are currently used to highlight any 
changes in clinical phenotype and also monitor responses to therapy.  The TEG assay 
in this project was used to measure the clot elasticity by using continuous graphical 
representation as the clot was formed.  This assay displays an image, derived from 
calculations made during the formation of the clot by the thromboelastograph, which 
represent the firmness of the clot (Figure 1.8).  The size and stability of the clot 
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formed was evaluated based on calculations obtained during physical formation of 
the clot.  Based on the nature of the sample, variable traces (Figure 1.9) were 
observed and their parameters recorded and analysed. 
 
Several groups have reported on the ability of rFVIIa to improve haemostasis, 
especially in haemophilia and other deficient disorders (Von Depka 2005; Lusher et 
al, 1998; Hedner and Ingerslev, 1999; Abshire and Kenet, 2004 (a); Gerotziafas et al, 
2004; Almeida et al, 2003; He et al, 2005; Galan et al, 2003; Goodnough, 2004; 
Sorensen et al, 2003 (a); Sorensen and Ingerslev, 2004 (b); Sorensen et al, 2005 (c)).   
 In addition to the above analyses, the TEG was used to observe the response to 
manipulation with infused rFVIIa in both the ICU samples and control samples.  The 
response to rFVIIa was analysed in both whole blood and plasma samples.   
 
Thrombin generation was carried out by a collegue, who was investigating thrombin 
generation in the same samples collected from the ICU patients.  With his 
permission, this data was included and evaluated along side the finding from this 
project.  This data is shown in Section 3.2.2. 
 
In order to analyse clot stability within a plasma system, another assay was used.  
The modified CLoFAL assay derived from the methods published by Lisman et al, 
2002 and Goldenberg et al, 2005 employs both clot formation and clot lysis.  
Because this assay quantitatively measures the rate at which the clot is formed or 
lysed, it was used to analyse the rate at which the formed fibrin clots within a plasma 
system where being cleared in the presence of a lysis trigger.  The rationale behind 
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this analysis was that the lower the rate of lysis, the more stable the clot is.  This 
analysis is highly influenced by the biochemical composition of the plasma but it 











MATERIALS and METHODS 
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2.1 CHEMICALS AND REAGENTS 
 
All chemicals, reagents and supplies were purchased from the stated sources. 
 
2.2 PATIENT SELECTION 
 
The investigations in this project were carried out on whole blood and plasma taken 
from three defined groups; healthy control group (n=14), haemophiliac A patients 
(n=9) and Intensive care unit (ICU) patients (n=12).  The haemophiliac patients are 
registered with the haemophilia care centre at Addenbrookes hospital while the ICU 
patients were enrolled from the intensive care unit at Addenbrookes hospital.  The ICU 
patient group samples were obtained from a clinically diverse group of patients whose 
underlying conditions for being in the ICU varied among each patient.  The reason for 
this unbiased selection was to assess the clotting profile in ICU patients as a whole 
rather than those with a particular associated disorder.  Ethical approval is included in 
Appendix I.  Only samples at baseline factor levels were taken from the haemophiliac 
subjects.  Alternatively, these haemophiliac subjects had to be free of replacement 
factor for a period of 72 hours or more. 
ICU samples were obtained from patients that indicated fragility in their haemostatic 
ability.  This involved a range of patients, from those with organ dysfunction to those 
who had undergone surgery during their duration at the hospital.  Confirmatory status 
of haemostatic profile was elucidated by analysis using haemostasis screening tests; as 
explained in Section 3.2. 
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2.3 SAMPLE ACQUISITION AND PREPARATION 
 
Venous blood samples were drawn from the arm by a phlebotomist into 3.8% (w/v) 
tri-sodium citrate (0.109M) and the blood reconstituted 9 part volumes of blood to 1 
part volume of citrate, in a Starstedt blood collection bottle (Starstedt, Numberecht, 
Germany).  These samples were centrifuged at 3000g for 10 minutes and the platelet 
poor plasma aliquoted into 2ml capacity cryovials and frozen at -80c for subsequent 
testing. 
 
2.4 REAGENT PREPARATION 
 
2.4.1 Phospholipid preparation 
Extrusion device (Avestin, Ottawa, Canada) 
Polycarbonate filters (Glen Creston, Middlesex, UK) 
Synthetic phospholipids in chloroform (Avanti polar lipids, Alabama, USA) 
 
Synthetic phospholipids in chloroform (Avanti polar lipids, Alabama, USA) were 
prepared as described by Falls et al (2000).  The lipids were combined in the required 
proportions of phosphatidylserine (PS), phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC).  The lipids were then dried under nitrogen at 45˚C for 30 
minutes and there after resuspended in HEPES buffer (50mM HEPES, 145mM NaCl, 
pH 7.1).  This mixture was passed through the extrusion device using a 100nm 
diameter polycarbonate filter.  Another extrusion step was run using a 50nm diameter 
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polycarbonate filter and the resultant vesicles stored at 4˚C until later use.  The final 
ratio of the phospholipid components was as follows: PS (20%)/PE (20%)/PC (60%). 
 
2.4.2 Tissue factor preparation 
Commercial thromboplastin tissue factor, Innovin, Sysmex UK Ltd, Milton Keynes, 
UK 
Working buffer: Thrombogram buffer 
Recombinant human tissue factor (TF), Innovin®, was purchased from Sysmex UK 
Ltd, Milton Keynes, UK. 
Tissue factor was diluted to the required working concentration using working buffer.  
Working buffer contained 20mM HEPES, 140mM NaCl, 5mg/ml BSA pH 7.4 
 
2.4.3 Tissue plasminogen activator (tpa) preparation 
Tissue plasminogen activator (2-chain tpa) , American Diagnostica Inc, Stamford, 
Connecticut, USA. 
HEPES buffer (3.5mM KCL, 137mM NaCl, 25mM HEPES, 3mM CaCl2, pH 7.4) 
 
Tissue plasminogen activator (tpa) was purchased from American Diagnostica Inc, 
Stamford, Connecticut, USA.  HEPES buffer was used to dilute a series of tpa 
concentrations as required. 
 
2.4.4 Recombinant human FVIIa preparation 
Recombinant activated factor seven (NovoSeven, eptacog alfa {activated}), Novo 
Nordisk, Bagsveard, Denmark 
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NovoSeven was a kind gift from the Haemophilia centre at Addenbrookes NHS 
Hospital.  Each vial contained 2.4mg/ml of lyophilised rFVIIa.  On reconstitution, 
with sterile water, each vial contained 2.4 mg/ml of novoseven. The reconstituted 
product contains no preservatives. NovoSeven contains trace amounts of proteins 
derived from the manufacturing and purification processes such as mouse IgG 
(maximum of 1.2 ng/mg), bovine IgG (maximum of 30 ng/mg), and protein from 
BHK-cells and media (maximum of 19 ng/mg).   
On reconstitution, rFVIIa was aliquoted and frozen at -80C for future use.  Stock 
solution of 10mg/ml, 1,86mg/ml and 0.6ug/ml were reconstituted and stored at -80C.  
Aliquots were thawed at room temperature for 5 minutes and immediately placed on 
ice and were used within 1 hour after thawing occurred. 
 
2.4.5 Calcium chloride 
Calcium chloride (volumetric solution of 1M), BDH, Poole, England 
 
Patient samples were recalcified by adding 0.2M CaCl2 (reconstituted from 1M CaCl2 
in 25mM HEPES buffer containing 140mM NaCl, p.H 7.4) 
 
2.4.7 Multi-channel discrete analyser (MDA) series analyser reagents.  
  
Devices and utilities used included: 
a. MDA series coagulation analyser (Trinity Biotech, Sulhamstead,  Theale, 
UK) 
b. Disposable cuvettes (Trinity Biotech, Sulhamstead, Theale, UK) 
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c. Imidazole buffer, (Trinity Biotech, Sulhamstead, Theale, UK) 
d. Platelin LS and CaCl reagent (Trinity Biotech, Sulhamstead, Theale, UK) was 
used in APTT-based assays in plasma.  The assay works by employing a 
phospholipid reagent with activators as well as a calcium chloride reagent 
e. MDA D-dimer kit (Trinity Biotech, Sulhamstead, Theale, UK) assay is based on 
a homogenous latex particle based immunoassay for the quantification of 
cross-linked fibrin degradation products containing the D-dimer domain in 
plasma.  
f. MDA Fibriquik kit (Trinity Biotech, Sulhamstead, Theale, UK) is bovine 
thrombin reagent for the use in the quantitative determination of fibrinogen 
levels. 
g. Simplastin rHuTF (Trinity Biotech, Sulhamstead, Theale, UK) is a tissue 
thromboplastin reagent derived from cultured human cells used to determine 
the prothrombin time in plasma.  
h. Factor deficient plasma (Trinity Biotech, Sulhamstead, Theale, UK). These are 
intended for the quantification of respective factors in patients suspected of 
diminished or absent coagulation protein levels.  [Levels analysed included FII, 
FV, FVII, FVIII and FX] 
i. Reference material (Technoclone, Vienna, Austria) 







2.5 FULL BLOOD COUNT (FBC) 
Beckman-Coulter analyser, High Wycombe, Buckinghamshire, UK 
Diluents and Reagent kit solution, Beckman-Coulter, California, USA 
 
Full blood count tests were carried out on the Beckman coulter analyser.  The main 
parameters of this test include white cell count, haemoglobin estimation, red cell 
count, mean cell volume, mean cell haemoglobin, mean cell haemoglobin 
concentration and platelet count.  The FBC is mainly used as a screening test to 
indicate levels of anaemia and infection.  The platelet count is critical in the 
haemostatic process as it is an indicator of thrombocytopaenia. 
 
Assay method: 
Venous blood samples were obtained from patients using recommended the protocol 
into  1.6Mg/ml EDTA in a S-monovette Starstedt collection bottle (Starstedt, 
Numberecht, Germany) and were handled and processed according to the 
recommended laboratory protocol (sufficiency, clots and correct labelling).  Once 
analysed, the samples were authorised and results transferred to the laboratory 
information systems.   
Reference ranges and units (age and sex-linked) were defined on the laboratory 








ROTEM (Pentapharm GmbH, Munich, Germany) {Figure 2.1} 
Disposable cups and pins (Pentapharm GmbH, Munich, Germany) 
Relipidated tissue factor  
0.2M CaCl  
 
Principle of the method: 
Blood is added into disposable cuvette in heated cuvette holder and the disposable pin 
(sensor) is fixed on tip of rotating axis as shown in figure 2.1.  The axis is guided by 
high precision ball bearing system and the axis rotates back and forth.  This axis is 
connected with spring for measurement of elasticity. The exact position of the axis is 
detected by reflection of light on small mirror on axis. The data is then obtained and 
analysed on computer.  The loss of the elasticity when the sample clots leads to a 
change in the rotation of the axis and so this is represented as a visual trace called a 
thromboelastogram (Figure 1.10). 
  






The analyser was switched on and allowed to warm up to 37C.  Cup carriers, to be 
used for analysis, were carefully removed and placed on the heated area at the front of 
the instrument to maintain the carrier temperature at 37C.  Cup and pin were taken 
from the box, ensuring that only the exterior of the cup surface was touched.  If the pin 
was touched, then both the cup and pin were discarded.  Holding the outside of the 
cup, the pin on the carrier spike for the channel to be used was located.  The cup was 
placed in the cup carrier and sample processing and analysis commenced.   
 
Performing the analysis 
The channel number and tests to be used were selected from the software.  Using the 
electronic pipette, the instructions on screen were followed for sample and reagent 
delivery (with whole blood, the sample must be fully mixed by gentle inversion and all 
testing preformed within 2 hours post venapuncture).  A pronounced variance in the 
TEG parameters is obtained within the first 30 minutes after blood is taken, all 
samples were rested for 30 minutes before analysis (Sorensen et al, 2003)The cup was 
carefully slid into position, ensuring that the two pins at the back secured the cup 








 A volume of 20l of relipidated tissue factor was added to the cup followed by 20l 
of CaCl2.  After the addition of 300l of test sample, the cup was adjusted on to the 
pin and the thromboelastograph trace initiated as explained above. 
Parameters measured and reference ranges 
Parameters measured are shown in Figure below (Figure 2.2).  The numerical data can 
be compared to the provisional reference ranges.   
 
 
Figure 2.2 Thromboelastograph trace (Figure obtained from www.pentapharm.de) 
 
Parameter Range Units 
CT 420-750 sec 
CFT 75-420 sec 
Angle 30-63 degrees 
MCF 41-63 mm 
ML 1-10 % 
Table 1.2 Reference ranges and units (Provisional ranges n=8) (CT, Clotting time; CFT, Clot 
formation time; MCF, Maximum clot formation; ML, maximum lysis; LI30, Lysis index 30).   
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2.7 CALIBRATED AUTOMATED THROMBIN GENERATION 
ASSAY 
Fluoroscan Ascent (Thermolabsystems OY, Helsinki, Finland) 
Thrombinoscope software (Synapse BV, Maastricht, Netherlands) 
Microplates; 96 wells (Greiner Bio-one Ltd, Storehouse, UK) 
Fluorogenic substrate Z-Gly-Gly-Arg-AMC (Bachem, Dubendorf, Switzeland) 
Phopsholipid vesicales (section 2.4.1) 
Recombinant human TF, innovin (Sysmex Ltd, Milton Keynes, UK) 
Dimethyl sulphoxide (DMSO) (Sigma Aldrich Ltd, Poole, UK) 
Calcium chloride (BDH Ltd, Poole, UK) 
Bovine serum Albumin (BSA) (Sigma Aldrich Ltd, Poole, UK) 
20mM HEPES buffer 
Thrombin calibrator (Synapse BV, Maastricht, Netherlands) 
 
This assay (Hemker et al, 2003) was conducted with 20µl of buffer (20mM HEPES 
buffer, 140mM NaCl, 5mg/ml BSA, pH7.4) containing lapidated TF which was added 
to the microplate and 80µl of sample added to these wells.  Substrate reagent, 20µl, 
(2mM BSA, pH 7.4) 20mM HEPES, 60mg/ml BSA, pH 7.4) and 100µl 1M CaCl2, 
25µl of fluorochrome in 100mM DMSO were added and the reaction monitored using 
the thrombinoscope software. Contact factor activation was eliminated using corn 
trypsin inhibitor (CTI).    Thrombin generation was carried out by a colleague, who 
was investigating thrombin generation in the same samples collected from the ICU 




2.8  COAGULATION LABORATORY ANALYSIS 
 
The multi-channel discrete analyser (MDA) series analyser was used to test plasma 
components of citrated samples taken from ICU patients 
 
2.8.1 MDA prothrombin time (PT) 
MDA series coagulation analyser (Trinity Biotech, Sulhamstead,  Theale, UK) 
Disposable cuvettes (Trinity Biotech, Sulhamstead, Theale, UK) 
Imidazole buffer, (Trinity Biotech, Sulhamstead, Theale, UK) 
Simplastin rHuTF (Trinity Biotech, Sulhamstead, Theale, UK) 
 
Addition of tissue thromboplastin, phospholipid and calcium ions to citrated plasma 
induces clotting, based on the principle shown in Figure 2.3.  The clotting time 
depends upon the levels of FII, FV, FVII and FX (these are factors that constitute the 
extrinsic pathway/tissue factor pathway).  The laboratory reference range was 11-14 
seconds (mean normalised PT = 12.2 seconds) 
 
Figure 2.3 Principle of the PT assay on the MDA 
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2.8.2 MDA Activated partial thromboplastin time (APTT) 
MDA series coagulation analyser (Trinity Biotech, Sulhamstead,  Theale, UK) 
Disposable cuvettes (Trinity Biotech, Sulhamstead, Theale, UK) 
Imidazole buffer, (Trinity Biotech, Sulhamstead, Theale, UK) 
Platelin LS and CaCl reagent (Trinity Biotech, Sulhamstead, Theale, UK) 
 
In order to activate the contact factors in the intrinsic pathway, contact activation is 
used and this is facilitated by the large anionic surface area of the added micronized 
silica.  On addition calcium and phospholipid, the time for clot formation is dependent 
on the presence of clotting factors in the intrinsic pathway as shown in Figure 2.4.  








2.8.3 MDA Clauss fibrinogen assay 
MDA series coagulation analyser (Trinity Biotech, Sulhamstead,  Theale, UK) 
Disposable cuvettes (Trinity Biotech, Sulhamstead, Theale, UK) 
Imidazole buffer, (Trinity Biotech, Sulhamstead, Theale, UK) 
MDA Fibriquik kit (Trinity Biotech, Sulhamstead, Theale, UK) 
 
This automated fibrinogen test relies on the principle that fibrinogen is transformed 
into fibrin in the presence of excess thrombin.  Thrombin is incubated with diluted 
patient plasma and the clotting time is inversely proportional to the concentration of 
fibrinogen concentration in the sample. The concentration of fibrinogen present in the 
sample is calculated from a calibration curve derived by the software.  Reference 
range 1.5-4.5g/L (mean + 2SD, n=40). 
2.8.4 MDA D-Dimer assay 
MDA series coagulation analyser (Trinity Biotech, Sulhamstead,  Theale, UK) 
Disposable cuvettes (Trinity Biotech, Sulhamstead, Theale, UK) 
Imidazole buffer, (Trinity Biotech, Sulhamstead, Theale, UK) 
MDA D-dimer kit (Trinity Biotech, Sulhamstead, Theale, UK 
This is a latex based immunoassay that measures D-dimer antigen present in plasma as 
a result of fibrin clot degradation by plasmin.  Elevated levels are associated with 
secondary fibrinolysis following clot formation.  Latex particles coated with a mouse 
monoclonal D-dimer antibody are added to diluted plasma which allows the particles 
to agglutinate in the presence of D-dimers.  There is a positive correlation of the D-
dimer concentration to the rate of agglutination of the particles.  D-dimer levels are 
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measured as µg FEU/L (fibrinogen equivalent units per litre). Normal range is <500 
µg FEU/L. 
 
2.8.5 MDA PT-based assays for FII, FV. FVII and FX 
MDA series coagulation analyser (Trinity Biotech, Sulhamstead,  Theale, UK) 
Disposable cuvettes (Trinity Biotech, Sulhamstead, Theale, UK) 
Imidazole buffer, (Trinity Biotech, Sulhamstead, Theale, UK) 
Platelin LS and CaCl reagent (Trinity Biotech, Sulhamstead, Theale, UK) 
Simplastin rHuTF (Trinity Biotech, Sulhamstead, Theale, UK) 
Factor deficient plasma (Trinity Biotech, Sulhamstead, Theale, UK) 
 
This is a one-stage assay based on the PT that relies on the patient sample plasma 
correcting the clotting time of the kit’s deficient plasma.  By adding the respective 
deficient substrate plasma allows for the detection of any correction that may occur as 
a result of adding patient sample plasma.  The prolongation of the test time is 
proportional to the respective factor level present in the patient sample.  Sample factor 
levels are calculated from a standard reference curve derived from dilutions of the 
commercial normal reference plasma.  Results are reported as a percentage of the 
activity by extrapolation from the reference curve. 
 Reference ranges: 
 FII = 50-200 IU/dL (Dacie and Lewis, 2006) 
 FV = 50-200 IU/dL (Dacie and Lewis, 2006) 
 FVII = 63-171 iu/dL (n=20, sept. 1996) 





2.8.6 MDA APTT-based assays for FVIII 
MDA series coagulation analyser (Trinity Biotech, Sulhamstead,  Theale, UK) 
Disposable cuvettes (Trinity Biotech, Sulhamstead, Theale, UK) 
Imidazole buffer, (Trinity Biotech, Sulhamstead, Theale, UK) 
Platelin LS and CaCl reagent (Trinity Biotech, Sulhamstead, Theale, UK) 
Simplastin rHuTF (Trinity Biotech, Sulhamstead, Theale, UK) 
Factor deficient plasma (Trinity Biotech, Sulhamstead, Theale, UK) 
 
 
This is a one-stage assay based on the APTT that relies on the patient sample plasma 
correcting the clotting time of the kit’s deficient plasma. By adding the respective 
deficient substrate plasma allows for the detection of any correction that may occur as 
a result of adding patient sample plasma.  The prolongation of the test time is 
proportional to the respective factor level present in the patient sample.  Sample factor 
levels are calculated from a standard reference curve derived from dilutions of the 
commercial normal reference plasma.  Results are reported as a percentage of the 
activity by extrapolation from the reference curve. 
 Reference range: 








2.9 CLOT LYSIS ANALYSIS 
 
2.9.1 Clot lysis assay 
Phospholipid, 100uM 
Tissue factor, 9.3pM 
Tpa, 5µg/ml 
CaCl2, 0.2mM 
Multiscan Ascent microplate reader (Thermo Labsystems, Basingstoke, UK) 
Microtitre plates (96 wells) (Bachem UK Ltd, St. Helens, UK) 
 
This method of investigation was based on the procedure used by Lisman et al, 2002 
and Goldenberg et al, 2005.  Reagent concentrations were optimised for this assay as 
described in Chapter 3.  Platelet poor plasma samples were thawed at 37˚C and placed 
on ice until the time of assay but did not exceed 25 minutes incubation on ice.  
Reaction lysis buffer was prepared from tpa (3g/ml), phospholipid (100M), CaCl2 
(0.2M) and tissue factor (9.3M) all which were added to buffer and to give the 
following final concentrations (tpa; 375ng/ml, PL; 12.5M, CaCl2; 2.5mM and TF; 
1.1625M) after addition of the reactant solution to plasma samples.   
 
For each patient sample tested, 85L of freeze-thawed plasma was dispensed into each 
of 3 wells of a 96-well plate (with reagent blank in the fourth) and 85L of reactant 
solution was added simultaneously to the remaining wells.  The plate was then placed 
in a microplate reader and dual kinetic absorbance measurements at 405nm 
wavelength, at 45 second intervals, for 5 hours were recorded.  The spectrometer 
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interfaces with a computer in that all its operations such as continuous analysis of 
absorbance using the software can be automated.  Absorbance data was blanked by the 
reagent in order to eliminate artefact changes in baseline absorbance due to lipaemic 
plasma.  Blanked absorbance data was then averaged at each time point for the 
triplicate wells.   
Data retrieved from this experiment was based on the increase in light absorbance, 
which is proportionate to the maximum amplitude.   Likewise, the decline in 
absorbance is relative time taken for the maximum amplitude to reduce to its lowest 
level.  The rate of clot formation is therefore represented by the phase that reaches 
maximum amplitude and the rate of clot lysis is represented by the phase that reaches 
minimum amplitude.   
 
2.10 STATISTICAL ANALYSIS 
 
The non-parametric Kruskal-Wallis test was used to test the variation between groups 
and one-way analysis of variance (ANOVA) was used for changes before and after 
addition of rFVIIa.  GraphPad prism statistical software package (GraphPad Software, 





















3.1  ANALYSIS OF THE CLOTTING PROFILE OF 
WHOLE BLOOD 
 
 3.1.1 Platelet counts among patient groups  
As part of the preliminary investigations, platelet counts were measured in whole 
blood samples obtained for each patient group.  Platelet counts ranged from  
118-305.5x10
9
/L in Healthy volunteers (n=14),  
143.3-311.0 x10
9
/L in haemophiliacs (n=7) and  
12.20-451.1 x10
9
/L in ICU (n=12) samples.   
The group platelet count means were 228.9+20.10 x10
9
/L (healthy volunteers), 
224.9+20.19 x10
9
/L (haemophiliacs) and 177.5+38.59 x10
9
/L (ICU) as shown in 
Figure 3.1.  No statistical significance was observed between the healthy volunteers, 








Figure 3.1 Platelet counts for respective patient groups for whole blood samples collected. 
Healthy volunteer controls (n=14), haemophiliacs (n=7) and ICU (n=12) 
 
CONCLUSION:  The variation within these counts is more noticeable in the ICU 
patient group (showing a range of 12.20 - 451.1 x10
9
/L) than the healthy volunteer or 
























haemophiliac group.  The underlying pathology in these individuals could play a role 
in the platelet levels noted in this ICU group.  Other coagulation data that further 
support this deduction is shown below.   
 
3.1.2 Whole blood (WB) clotting profile among patient groups using the 
thromboelastogram 
Prior to the investigation of thrombin production and fibrin formation in a plasma 
system, whole blood profiles of the samples obtained from each individual within the 
respective patient group were analysed.  Previous investigations have shown that 
platelet counts affect the rate of clot formation and the size of the clot formed (i.e. the 
maximum amplitude of the clot as measured on the ROTEM).  In addition, the 
presene of rFVIIa improves the time and rate of clot formation (Gerotziafas et al, 
2004, Gabriel et al, 2004, Sorensen and Ingerslev, 2004).   
 
The aim of this investigation was to initially assess the ex vivo clotting profile of 
each sample taken from each individual within the patient group.  In addition, later 
on the responses of these samples to rFVIIa was also investigated.   
 
Figure 1.12 shows a traditional thromboelastograph trace with an illustration of the 
dynamic profile after a raw signal has been applied to a sample for clotting to initiate.  
This pattern was analysed during the thromboelastographic investigation of 
coagulation in normal, haemophiliac and ICU whole blood samples.  The clotting 
time (CT) corresponds to the initiation phase of clot formation.  The maximum clot 
firmness (MCF) is the measure of the impact on clot elasticity of the platelet count 
 
92 
and fibrinogen concentration and the clot angle () correspond to the size of the clot 
formed and the rate at which it progresses.   
 
ROTEM was carried out on native blood samples (Figure 3.2A) and subsequently, to a 
second aliquot of that sample to which, 5l of (giving a final concentration 8.82g/ml) 
rFVIIa was added (Figure 3.2B).   In all samples, a profile of real time continuous 
plasma clot formation was recorded by a ROTEM analyser as explained in Section 
2.6.  Coagulation was initiated by addition of 20µl of 0.2M CaCl2 and 20µl of 1: 1000 






















Figure 3.2 ROTEM parameters on whole blood recorded on healthy volunteers, haemophiliac and ICU samples.  Graphs show clot profiles pre (A) and post 
(B) 8.82g/ml infusion of rFVIIa.   Data is represented as the mean +SEM.  CT, clotting time; CFT, clot formation time; MCF, Maximum clot formation; , 























































































CONCLUSION:  The results presented in Figure 3.2A show thromboelastograph 
analysis carried out on native whole blood activated by just the addition of CaCl2.  
These results show a marked difference in clot formation especially within the 
haemophiliac group.  The CT and CFT within the haemophiliac group was 
characterised by prolonged clotting times and slow progression of clot formation in 
comparison to the healthy volunteer group and ICU group.  The clotting times in the 
healthy volunteer and ICU whole blood were similar.  Non-parametric analysis 
(Kruskal Wallis test) was carried out to analyse variation between the groups in the 
absence of rFVIIa and showed that inter-variation among the groups was as follows: 
CT, p=0.052; CFT, p=0.0105; , p=0.0032; there was no statistical variation in the 
MCF among these groups.  Table 3.1 shows the 2 samples from the haemophilia group 







 Normal Haemophiliac ICU 
CT (sec); NR:450-690sec 
Range 457 – 708 
(215-344) 
635.0 – 5529 
(347-689) 
420 – 1370 
(264-1034) 







CFT (sec); NR:120-450sec 
Range 146 – 782 
(56-181) 
391 – 3720 
(89-160) 
111 – 2142 
(63-691) 







MCF (mm); NR:34-46mm 
Range 43 – 61 
(53-62) 
21 – 66 
(51-89) 
26 – 63 
(32-63) 







Clot angle,  (˚); NR:36-48 
Range 41.50 – 63 
(60-78) 
0 – 35 
(60-72) 
0 – 68 
(26-77) 







Table 3.1 TEG parameters on native whole blood samples taken from healthy volunteers, 
haemophiliac and ICU samples; unbold Figures. TEG parameters on native whole blood samples 
from each respective group with the addition of rFVIIa; bold Figures in brackets.  (The normal 
ranges (NR) are TEG manufacturer normal ranges.) [n=9, n=7 and n=10 respectively] CT, 
clotting time; CFT, clot formation time; MCF, Maximum clot formation; , clot angle; rFVIIa, 






However, following the addition of 5µl of rFVIIa, the dynamics of clot formation 
shifted as shown in the bottom row in Figure 3.2 marked with the B.  The greatest 
response to rFVIIa in respect to the ROTEM parameters was predominantly noted 
within the haemophiliac group (Table 3.2).  Figure 3.2B shows thromboelastograph 
analysis of clot formation in whole blood activated with CaCl2 in the presence of 
rFVIIa. The addition rFVIIa normalised all four parameters analysed using this assay 
in all three sample groups.  Statistical analysis showed that there was no variation 
between the respective study group, in all four parameter, after the addition of rFVIIa 
(p>0.05).  Within each study group, the most noticeable changes were noted in the   









Table 3.2 Percentage change in parameters after 5µl of 8.82µg/ml rFVIIa infusion into each respective group sample.   CT, clotting time; CFT, clot 




 CT (decrease) CFT (decrease) MCF(increase) (increase) 
Normal 52% 62% 15% 39% 
Haemophiliac 80% 84% 21% 76% 
ICU 33% 57% 0.09% 26% 
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CONCLUSION: The initiation and propagation stages of thromboelastometry trace 
recording before the ex vivo addition of rFVIIa in each of the patients is most marked 
in the haemophiliac samples compared to samples from healthy volunteers and ICU 
samples.  This might be attributed to the fact that intrinsic factors (FVIII and FIX) are 
deficient in the haemophiliac group whereas some of the results observed in the ICU 
group could be due to an acute phase response in these patients (see Section 3.2.1).  





3.2 PLASMA SAMPLE ANALYSIS 
3.2.1 Routine coagulation tests and coagulation factor levels in the ICU 
group 
Although the ROTEM, as a global assay, proves a reliable indicator of the clotting 
status, more specific tests were performed to support the results obtained from the 
ROTEM assay.  The strength of a Table clot is largely influenced by the presence of 
platelets in the whole blood system but in the plasma system this is comparable with 
fibrin formation.   
 
Conventionally, clotting screen tests (PT and APTT) are carried out when a 
haemorrhagic or thrombotic disorder is suspected.  The APTT is prolonged when there 
is a deficiency of one or more of the intrinsic factors or when fibrinogen levels in 
blood are decreased.  Other circumstances where the APTT may be prolonged include 
the presence of specific inhibitors to circulating factors, non-specific inhibitors like 
lupus anticoagulant, interfering substances like fibrin degradation products or 
paraproteins.  When both the APTT and the PT are prolonged and other factors like 
liver disease, uraemia, disseminated intravascular coagulopathy, oral anticoagulation 
or vitamin K deficiency have been excluded, then a single-factor deficiency can be 
suspected. A prolonged PT in conjunction with other tests is usually consistent with 
FVII deficiency and subsequently, diagnosis of a single factor deficiency is carried out 
using a one-stage PT-based assay.   
 
  The aim of this investigation was to assess the coagulation profile of the ICU group 
samples within a plasma system.  Screening tests and single factor tests were 
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performed on the plasma samples as outlined in Section 2.7 (see Appendix i and ii).  
Factor assay reference ranges were standardised in-house, or in accordance with Dacie 
and Lewis, 2006 or commercially (Trinity Biotech, Sulhamstead, Theale, UK).  
Coagulation tests carried out on ICU samples are shown in Figures 3.3a-d.  In addition 
healthy volunteers and haemophilia samples were also analysed.  A summary of this 







Table 3.3 Summary of results derived from coagulation factor assays in ICU plasma samples.  RR, Reference range; DD, d-dimer; Fbg, Fibrinogen; PT, 
Prothrombin time; APTT, Activated partial thromboplastine time;  FII,V,VII,VIII and X, Factor II,V, VII, VIII and X
Factor (RR) Range Median Mean+SEM 
DD (<500 FEU) 836.6 – 11,020 1845 3673 + 942.2 
Fbn (1.5-4.0 g/dL) 1.06-6.29 3.07 3.166 + 0.43 
PT (11-14 sec) 14.1 – 25.20 17.6 18.05 + 1.197 
APTT (24.5-34.5sec) 26.7 – 83.5 46.20 45.54 + 4.967 
FII  (70-100 IU/dL) 27-79 46.5 45.83 + 4.474 
FV (70-150IU/dL) 23-160 61.5 71.83 + 1.64 
FVII (70-150IU/dL) 11-83 50 50.25 + 7.22 
FVIII (50-150IU/dL) 92 - 277 165 173.5 + 18.20 
FX (70-150IU/dL) 33 - 123 56 57.92 + 6.980 
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Non-parametric statistical analysis on the ICU patient group data showed statistical 
variation in comparison to the healthy volunteer group when data from coagulation 
factor assays was analysed (PT, p=0.0002; APTT, p=0.0004; FII, p=0.0001; FVII, 
p=0.0044; FVIII, =0.0001; FX, p=0.0005). The D-Dimer levels were only tested in the 
ICU patient group.  The D-Dimer levels in the ICU samples were elevated above the 

























Figure 3.3a Clotting screens tested on platelet poor plasma n=10, Healthy volunteers; n=9, 
haemophiliac; n=11, ICU samples.  (Haem-haemophilia group).  Data points in each group are 
expressed as the mean of duplicate runs and the bars represent the mean of all the data points 
plotted within each sample group 
Prothrombin time
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Figure 3.3b Prothrombin and FV levels tested on platelet poor plasma n=10, healthy volunteers; 
n=9, haemophiliac; n=11, ICU samples (Haem-haemophilila group). FII, factor II; FV, Factor V.  
Data points in each group are expressed as the mean of duplicate runs and the bars represent the 
mean of all the data points plotted within each sample group 
Factor II











































Figure 3.3c Factor FVII and FVIII levels tested on platelet poor plasma n=10, healthyvolunteers; 
n=9, haemophiliac; n=11, ICU samples (Haem-haemophilila group) FVII, factor VII; FVIII, 
Factor VIII.  Data points in each group are expressed as the mean of duplicate runs and the bars 
represent the mean of all the data points plotted within each sample group 
Factor VII

































Figure 3.3d FX levels tested on platelet poor plasma n=10, healthy volunteers; n=9, haemophiliac; 
n=11, ICU samples (Haem-haemophilila group) FX, factor X.  Data points in each group are 
expressed as the mean of duplicate runs and the bars represent the mean of all the data points 




CONCLUSION: Within the ICU group, coagulation factors are significantly lower 
than the reference ranges (section 2.7).   These results are consistent with the 
prolonged clotting screens observed.  FVIII and fibrinogen levels were elevated; this 
could be consistent with an acute phase reaction in these patients.  The raised DD (D-
Dimer) levels will also have a significant effect in the stability of the clot formed.  
Comparatively, factor levels for the healthy volunteers and haemophilia groups were 
also assayed and are shown in Figures 3.3a-d. 
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3.2.2 Thrombin generation in the ICU sample group 
The generation of FXa in haemophilia is reduced on the surface of the platelet due to 
the deficiency of in the Tenase complex.  This results in insufficient thrombin 
generation, which ultimately leads to the reduction of thrombin-dependent clotting 
processes.  This suggests that FVIII and FIX on the platelet surface have a regulatory 
role on the generation of thrombin.   
 
The curve (Figure 1.3, blue trace) created during thrombin generation reflects the 
actions of the total haemostatic mechanism.  The endogenous thrombin potential 
depicted as the area under the curve represents the pattern of thrombin formation.  In 
this investigation, thrombin generation was measured in platelet poor plasma (PPP) 
samples collected from ICU patients and analysed.  This analysis was carried out by a 
colleague who was analysing thrombin generation in this patient group. 
 
Thrombin generation analysis was carried out as described in Section 2.7.  The ICU 
plasma samples (80µl) were analysed and the reaction monitored using the 
thrombinoscope software.  Five parameters were observed, namely lag time (T1), ETP 
(endogenous thrombin potential), area under the curve (T4), peak of the curve (T3), 
time to the peak (ttPeak) [T2] and the start tail. 
 
Reference ranges for thrombin generation were established from plasma samples taken 
from 16 healthy subjects.  These values are currently under further assessment as 
laboratory reference ranges. The reference ranges to date are shown (mean +/- 2SD) 
below in Table 3.3. 
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Variable PPP n=16 
Lagtime (min) 4.1-6.5 
ETP (nmol.min) 114-2272 
Peak (nmol) 92-287 
ttPeak (mins) 8.5-12.5 
Start tail (min) 25.1-35.3 
Table 3.3 Thrombin generation references ranges and units.   ETP, Endogenous thrombin 
potential; ttPeak, total time to peak 
 
 
Analysis was carried out for the total thrombin generation potential within the ICU 
patient group (Table 3.4).   Contact factor activation was eliminated as a pre-analytical 
variable using CTI.  Of the 11 samples tested from the ICU group, one sample failed 























Table 3.4 Thrombin generation evaluation in ICU (samples n=11).  
#
 One of the samples did not show any thrombin generation capacity (bold and italics) 
ETP, Endogenous thrombin potential; ttPeak, total time to peak 
Sample Lag time ETP Peak ttPeak Start tail 
1 20.50 720.5 55.40 27.0 54.0 
2 6.40 1290.0 113.50 11.1 41.5 
3 6.30 1138.0 119.60 10.7 39.0 
4 11.70 958.5 115.70 16.1 39.5 
5 13.20 653.5 71.50 18.0 42.0 
6 8.70 1727.0 138.10 13.7 51.0 
7 21.70 597.0 37.40 31.2 57.0 
8 #         - 0.0  - - - 
9 7.00 1524.5 128.80 15.1 42.0 
10 14.50 1358.5 - 119.24 19.13 
11 6.75 1402.5 - 166.11 10.88 
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In relation to the reference ranges, initiation of thrombin generation (11.68 + 1.827),  
the ttpeak (42.83 + 17.15) and the start tail (39.60 + 4.594)  were markedly reduced in 
ICU samples The average ETP (1034 + 152.2) in these samples was also reduced 
which could indicate a reduced rate of thrombin generation.  The time taken for the 
thrombin concentration to return to baseline was markedly prolonged.   
 
CONCLUSION: The thrombin generation in the ICU sample group demonstrated a 
prolonged initiation stage and the total thrombin generated in this sample group was 
reduced.  The prolonged start tail observed could suggest a diminished stability of the 











3.3  INVESTIGATION OF CLOTTING PROFILE WITHIN A 
PLASMA SYSTEM  
 
3.3.1 Profile of fibrin clot formation in a plasma system  
Following the preliminary analysis of whole blood profiles (Section 3.1), investigation 
of fibrin formation in a plasma system was analysed.  Previous investigations have 
shown that addition of rFVIIa improved both the time and rate of clot formation 
(Gabriel et al, 2004; Sorensen and Ingerslev, 2004; Collins et al, 2006).   
 
In Sections 3.1 – 3.2, the results demonstrated that haemostasis in ICU patient samples 
was altered compared to samples from the healthy volunteer group.  Furthermore, the 
addition of rFVIIa normalised or enhanced the production of thrombin and clot 
formation.  The aim of analysing fibrin clot formation in a plasma system was to 
assess the in vitro clotting profile in these samples, in a non-cellular system looking 
only at the interaction of plasma components. 
 
Samples were analysed using the ROTEM assay as explained in Section 2.6 and only 
altered when the infusion of 5µl of the rFVIIa, at variable concentrations, (see 








































 Figure 3.4a Clotting times (seconds) and the rate of clot formation (CFT) recorded 
during plasma analysis of the with the ROTEM assay. Graph shows healthy volunteers (blue, 
n=10), Haemophiliac (red, n=9) and ICU (green, n=11) samples. CT, clotting time.  Data points in 
each group are expressed as the mean of triplicate runs and the bars on each graph represent the 
mean of all the data points plotted within each sample group 
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 Figure 3.4b Maximum clot formation (MCF) and clot angle recorded during plasma 
analysis of the with the ROTEM assay. Graph shows healthy volunteers (blue, n=10), 
Haemophiliac (red, n=9) and ICU (green, n=11) samples. Data points in each group are expressed 
as the mean of triplicate runs and the bars on each graph represent the mean of all the data points 
plotted within each sample group 
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Figure 3.5 Clotting times (seconds) recorded during plasma analysis with the ROTEM assay in healthy volunteers (blue, n=10), Haemophiliac (red, n=9) and 
ICU (green, n=11) samples. CT, clotting time; rFVIIa, recombinant activated FVII.  Data points in each group are expressed as the mean of triplicate runs 








































































Figure 3.6 Rate of clot formation recorded as the clot formation time (seconds) recorded during plasma analysis with the ROTEM assay in healthy 
volunteers (blue, n=10), Haemophiliac (red, n=9)) and ICU (green, n=11) samples. CFT, clot formation time; rFVIIa, recombinant activated FVII.  Data 
points in each group are expressed as the mean of triplicate runs and the bars on each graph represent the mean of all the data points plotted within each 
sample group 
 





















































Figure 3.7 Maximum clot firmness of the clot (mm) recorded during plasma analysis with the ROTEM assay in healthy volunteers (blue, n=10), 
Haemophiliac (red, n=9)) and ICU (green, n=11) samples. MCF, maximum clot formation; rFVIIa, recombinant activated FVII.  Data points in each group 
are expressed as the mean of triplicate runs and the bars on each graph represent the mean of all the data points plotted within each sample group 

























































Figure 3.8 Clot angle (degrees) recorded during plasma analysis with the ROTEM assay in healthy volunteers (blue, n=10), Haemophiliac (red, n=9)) and ICU 
(green, n=11) samples.  rFVIIa, recombinant activated FVII.  Data points in each group are expressed as the mean of triplicate runs and the bars on each 
graph represent the mean of all the data points plotted within each sample group 
 






































 Intra-variation within each group 
Figure 3.4 describes the clot formation parameters of the ROTEM within each sample 
group.  The start of fibrin clot formation and the rate at which this fibrin clot forms is 
shown in figure 3.4a.  Haemophilia sample group have a significantly higher clotting 
time than the healthy volunteer and ICU sample group, whose clotting times are 
similar.  According to this data, the time taken to clot formation is the same in the 
healthy volunteer and the ICU sample group.  However, once the fibrin clot is 
initiated, the rate at which more fibrin formation occurs is similar in the ICU and 
haemophiliac group.  Figure 3.4b represents the size of the fibrin clot formed.  The 
mass of the clot formed (MCF) is higher in the ICU sample group and the healthy 
volunteers than in the haemophilia group.   
 
Responses to rFVIIa within each sample group showed significant reduction in 
clotting time in response to all three concentrations of rFVIIa (normal = p<0.0001; 
Haemophiliac = p<0.01; ICU = p<0.002, ANOVA) as shown in Figure 3.5.  However, 
there was no statistically significant variation between the rFVIIa concentrations in the 
CFT, MCF and the clot angle within each of the patient groups. 
 
Inter-variation among the groups 
Clotting times: The haemophiliac and ICU samples demonstrated longer clotting times 
in comparison to samples from healthy volunteers.  The ranges of the clotting times 
were more noticeable within the haemophiliac group although this variation is not 
statistically significant (p>0.05 ANOVA).  Following the addition of rFVIIa, the 
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clotting times were reduced especially within the haemophiliac sample group.  All 
three groups showed that clotting times are responsive to rFVIIa infusion.   
Rate of clot formation: The clot formation times were longer in the haemophiliac and 
ICU sample groups.  Addition of rFVIIa increased the rate at which clots were formed 
on the ROTEM assay.  The fastest rate of clot formation was observed in the healthy 
volunteer sample group, followed by the haemophiliac group.  ICU samples showed 
little improvement in the rate of clot formation following the addition of rFVIIa to the 
plasma sample.  The rate of clot formation showed no statistical significance overall 
(p>0.05 ANOVA). 
MCF and the angle of the clot:  ICU samples demonstrated the highest MA of the clot 
as well as the angle of the clot.  The haemophiliac samples showed a varied but 
lowered MCF and clot angle size.  Following the addition of rFVIIa, there was a 
significant increase in both the MCF and clot angle (p<0.02 and p<0.01 respectively).  
There was no statistical significance in MCF and clot angle with increased rFVIIa 
infusion into the sample using ROTEM analysis in all three sample groups.  This may 
be indicative of the role played by rFVIIa at the initiation of fibrin clot formation 




3.4 ANALYSIS OF THE FIBRIN CLOT LYSIS PROFILE 
WITHIN A PLASMA SYSTEM 
3.4.1 Fibrin clot lysis  
In addition to the ROTEM, coagulation and thrombin generation tests, clot lysis assays 
were devised so as to analyse the stability of the plasma clot in ICU samples.   
An assay that employs both coagulation and fibrinolysis was used to assess the 
fibrinolytic potential in these samples.  Fibrinolysis plays a significant role in various 
haemorrhagic and prothrombotic conditions, just like the excessive fibrinolysis seen in 
severe haemophilia A, liver damage and the defective fibrinolysis observed in renal 
failure (Mosnier et al, 2001, Colluci et al, 2003, Lottermoser et al, 2001). 
 
This new global assay was used to simultaneously measure coagulation and 
fibrinolysis i.e. the clot formation and lysis assay (CLoFAL) assay.  This method is 
based on the procedure used by Lisman et al, 2002 and Goldenberg et al, 2005.  
Reagent concentrations were optimised for this assay as described in Section 3.6.  
Platelet poor plasma samples were thawed at 37˚C and placed on ice until the time of 
assay (for less than 25 minutes incubation on ice).  Reaction lysis buffer was prepared 
from tpa (3g/ml), phospholipid (100M), CaCl2 (0.2M) and tissue factor (9.3M) to 
give the following final concentrations (tpa; 375ng/ml, PL; 12.5M, CaCl2; 2.5mM 
and TF; 1.1625M) after addition of the reactant solution to plasma samples.   
 
All measurements and calculation were derived from a curve generated after an initial 
baseline absorbance at time T0 followed by a progressive rise in absorbance until 
maximum peak (MP) was reached at time T1.  This was followed by a phase of decline 
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in absorbance after which a late phase of decline to baseline in absorbance was noted 
at time T2.  This is illustrated in Figure 3.8b. 
 
 
Figure 3.8b Representation of the CLoFAL curve derived from standard normal pooled plasma, 






The clot lysis assay method has been adapted by generating a fibrin clot produced 
from platelet-poor plasma in a microtitre plate system and measuring the dissolution of 
these clots using an automated approach.  This is an extension of the previous analyses 
carried on the individual patient group samples.  This method requires an extended 
time period and sample incubation at 37C.  Samples were analysed using the 
CLoFAL assay as discussed in Section 2.6.  The Typical curves for healthy volunteer, 
haemophilia and ICU sample groups generated, using platelet poor plasma, are shown 
in Figure 3.9.   
 
3.4.2 Clot stability 
Figure 3.9 shows analysis of clot formation and lysis in platelet poor plasma from each 
respective patient group in the absence of rFVIIa.  The plasma samples were added to 
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a 96 well plate, in the presence of tpa to induce lysis, which was observed and 
recorded over 150 minutes.  The absorbance measured and recorded was calculated as 
the amount of light restricted through the sample as the clot formed and inversely as 
the sample lysed.   
Healthy volunteer plasma showed a gradual rise in clot formation.  The same pattern 
during the initiation phase of clot formation was noted in the ICU samples although 
active formation of the clot happened 5 minutes after the formation recorded in the 
healthy volunteer plasma samples.  The haemophiliac samples showed much lower 
maximum amplitude than the other sample groups.  The ICU and haemophilia samples 
did not show a decline in absorbance.  The change in the peak absorbance units 
(healthy volunteer 118.4, haemophilia A 86.66 and ICU 130.3) among the three 
groups is statistically significant (p<0.0001).   
 
CONCLUSION:  The variation in responses within each group could be an indication 

















Figure 3.9 Clot formation and lysis in the absence of rFVIIa using the CLoFAL assay in all three sample groups.  Healthy volunteers (blue, n=10), 
Haemophiliac (red, n=9)) and ICU (green, n=11) samples.  Data points in each group are expressed as the mean of triplicate runs 
Clot formation and lysis
































Patients in the intensive care unit (ICU) often present with a variety of pathophysiologic 
conditions that are associated with abnormal haemostasis. Bleeding is a major risk in 
patients with inherited or acquired coagulopathies.   Those experiencing massive trauma 
or undergoing major surgery also present a special challenge to the ICU. Bleeding 
complications usually result from abnormalities in platelets or deficiency of coagulation 
factors, reduced thrombin potential, and altered fibrinolytic pathway and  require 
specific blood or coagulation factor replacement. The development and advancement of 
diagnostic techniques and the availability of new potent therapeutic agents have 
improved the care for these patients.  
The data presented in the present studies has demonstrated that samples taken from ICU 
patients have abnormal coagulation.  These ICU samples had abnormal clotting screens 
with delayed initiation of haemostasis, which was measured by three low TF-activated 
global haemostasis assays, namely ROTEM, CAT and the CLoFAL assay systems.  
Clotting profiles in whole blood indicated a variation to that seen in plasma analysis.    
However, one common observation among between whole blood clotting and plasma 
clotting was that once haemostasis was activated, the propagation and formation of the 
clot was either normal in some ICU samples or enhanced.  This is explained further on. 
 
Currently, it has been proven that low tissue factor can activate haemostasis in vitro 
(Sorensen et al, 2004).  The rate at which the clot forms, particularly, the rate of 
thrombin production, is vital for stable fibrin clot formation (Mann et al, 2003 and 
Roberts et al, 2004).  Routine clotting screens are often prolonged in critically ill 
patients as demonstrated in this study.  However, these tests fail to reflect the 
haemostatic status of the patient.  It could be that the PT and APTT are depicting a 
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specific stage during the initiation phase in haemostasis where by the start of clot 
formation has been delayed by various factors such as the presence of increased 
inhibitors or contact factors.  Clinically, therapeutic intervention for prolonged clotting 
screens is FFP infusion, which based on the previous argument, may not be necessary 
unless the patient’s factor levels are significantly reduced.   The three global assays used 
in this study observed if there was a delay during the initiation of clot formation and it 
was demonstrated that there was a similarity in pattern of results demonstrated in the 
clotting screens and the global assays.  The CAT assay results showed that the initiation 
of thrombin generation in the ICU samples was delayed and the peak thrombin reduced, 
however the total amount of thrombin measured by the ETP was similar to the reference 
ranges derived from healthy subjects. Similarly, the time to clot formation in both the 
ROTEM and the CLoFAL assay was also delayed but the size of the clots and rate at 
which they were being formed was comparable to the healthy volunteer group and 
slightly enhanced in some of the ICU samples.   
 
The prolonged clotting screen and clotting times in conjunction with the slightly 
enhanced clot size recorded from these studies may be explained by the individual 
factor levels measured based on the current accepted models of haemostasis.  TF/FVII 
pathway activates coagulation, which leads to a small amount of thrombin being 
generated.  This thrombin is not enough to allow fibrinogen activation but is sufficient 
for FV and FVIII activation and the expression of negatively charged proteins on 
platelet surface.  The tenase complex of FIXa and FVIIIa, along with the 
prothrombinase complex of FXa and FVa localised on the platelet surface, drives the 
large thrombin burst required to form a stable clot (Mann et al, 2003 and Roberts et al, 
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2004).  Factors FII, FV, FVII and FX were decreased in the ICU sample group.  FVII is 
required during the initiation stage of thrombin production to activate FX to FXa so that 
the initial small amount of thrombin is generated.  This small amount of thrombin then 
activates FVIII and more platelets to bring about a much a larger thrombin burst.  A 
decrease in FVII and also FX may be consistent with insufficient thrombin production 
during the initiation step of coagulation.   These factors are required to activate factors 
V and VIII and to stimulate platelet expression of phospholipids.  Alternatively, FVIII 
levels were either normal or increased in ICU samples.    
 
4.1 Standard laboratory screening tests  
The prolonged PT and APTT tests and the delayed initiation of coagulation 
demonstrated by the global assays may communicate indistinguishable results in terms 
of the initiation of clot formation.  Speculatively, this may limit the effectiveness of the 
initiation time of the global assays and so other parameters that were measured and 
recorded may be of more use.  Even though collectively the ICU sample group in this 
study showed a somewhat prothrombotic state (Figure 3.2A, Table 3.4 and Figure 3.4b), 
singularly most samples showed parameters that were below the reference range (CFT 
and the MCF), which suggests an abnormality in clot formation.   
 
4.2 Whole blood analysis 
Thrombocytopaenia is a major complicating factor in the ICU setting.  In order to asses 
clotting in whole blood, a platelet count was initially conducted on each sample taken 
from ICU patients as well as the comparative control groups (haemophilia and healthy 
volunteer groups).  The main clinical significance of measuring the platelet count is that 
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it is a good indicator for increased bleeding risk.  This analysis was carried out first to 
ascertain what the platelet counts were in these samples and whether platelets influenced 
whole blood clotting profile when assayed using the ROTEM. 
Figure 3.1 illustrates the findings from the platelet counts carried out on all three patient 
groups.  The ICU samples demonstrated decreased platelet counts in comparison to the 
haemophilia and healthy volunteer group.  ICU samples also showed the widest range of 




/L.   
Whole blood analysis carried out on the ROTEM assay recorded four parameters.  The 
clot angle and maximum clot firmness (MCF) represents the size of the clot formed, 
which in whole blood analysis is influenced by the presence of platelets and other 
cellular components.   Figure 3.2A showed that MCF in the healthy volunteer group was 
similar to the ICU sample group but the haemophilia sample group showed the lowest 
MCF and clot angle.  thrombocytopaenia, as discussed in section 1.5.1, is a result of 
various factors.  The measurement of the platelet count is a specific single assay that is 
focussed on one aspect of haemostasis in these ICU samples.  It is represented as a 
single entity within a system where components of both primary and secondary 
haemostasis are being affected in various ways.  The ROTEM assay results shown in 
Figure 3.2A demonstrate that the clotting in whole blood from the ICU samples is 
comparable to the results seen in the healthy volunteer group.  This is inconsistent with 
the platelet count results.  However, it should be considered that without further clinical 
information on these patients, it is appropriate to wholly compare the clotting profile in 
these two study groups.  If there are predisposing factors such as sepsis, DIC or 
microangiopathy in the ICU group then it is likely that these are contributing to the 
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comparable MCF and clot angle in ICU sample group, especially if the DIC-contributing 
factors are favouring a hypercoagulable state.  During sepsis, the presence of 
haemophagocytosis may occur resulting in platelet clearance.  However the increase in 
inflammatory response will lead to increased thrombin production, which will 
subsequently favour a thrombogenic profile, as observed in microangiopathic patients.  
Therefore, even though platelet counts are low in the ICU sample group, the TEG data 
shows that this is not reflected in the ROTEM traces.   Speculatively, the variation in the 
plasma pro- and anti-coagulation proteins may play a significant role in this as discussed 
earlier.     
 
TF/FVIIa interaction is necessary for the initiation of haemostasis.  rFVIIa binds TF in 
the same manner that FVII binds TF during initiation.  rFVIIa has been shown to 
directly activate FX on the surface of locally activated platelets in vivo, which initiates 
the thrombin burst independently of FVII and FIX as well as TF.  The addition of rFVIIa 
to whole blood samples illustrated a haemostatic response as shown in Table 3.2.    The 
ICU sample group showed the least response to the addition of rFVIIa in comparison to 
the healthy volunteer group and the haemophilia group.  The CT represents the time it 
takes for the clot to start forming and the CFT represents the rate at which the clot is 
formed once the formation is initialised.  The time to CT in the ICU sample group was 
increased by 33% and CFT by 57% in the presence of rFVIIa but the MCF was not 
increased.  Addition of rFVIIa to these whole blood samples did not increase the MCF 
of the clots and since it had already been demonstrated that there were low platelet 
counts in this sample group, the platelet count could be one of the factors influencing the 
MCF.  Minute concentrations of thrombin produced during the initiation stage of 
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coagulation are sufficient for platelet, FV and FX activation in vivo but rFVIIa can 
mediate a large thrombin burst in the presence of phosphatidylserine, which is abundant 
in the cell membrane of platelets.  Therefore it would seem that the subsequent reactions 
during clot formation are influenced by both the cellular and plasma protein content.  If 
there is a deficiency of platelets and plasma factors initially then optimal thrombin and 
fibrin production will not be efficiently maximised, even in the presence of rFVIIa.  The 
highest response to rFVIIa was noted in the haemophiliac sample group.  The lack of 
FVIII in the haemophiliac sample group results in inefficient activation of FX (Section 
1.7.2).  According to the cell-based model of haemostasis, it isn’t that the TF-generated 
FX is insufficient but rather that it occurs on the wrong cell surface.  Normally, the 
FIXa/FVIIIa complex generated activates FX on the platelet surface during propagation 
and the TF/FVIIa activates FX on the TF-bearing cell.  FXa produced on the TF-bearing 
cell cannot move to the activated platelets because it is liable to inhibition by plasma 
FXa inhibitors, antithrombin and TFPI.  Normally during circulation, both TFPI and AT 
inhibit FXa rapidly and effectively, with a half-life of 1 minute or less for FXa in the 
fluid phase.  FXa that remains at the TF-bearing cell is protected from inhibition, 
whereas any FXa that diffuses from this cell surface is quickly inhibited.  This indicates 
that haemophilia is a result of failure of platelet-surface activation of FX.  The initiation 
and amplification stages of coagulation are relatively normal in haemophilia suggesting 
that the initial platelet plug can be formed but the thrombin burst necessary to stabilise 
this initial plug at the platelet surface cannot be generated.  Previous studies have shown 
that rFVIIa directly activates FX on the surface of locally activated platelets. This 
activation initiates the thrombin burst” independently of FVIII or/and TF.  Plasma factor 
levels in ICU samples are discussed further in Section 4.3. 
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 4.3 Fibrin clot formation  
In order to analyse clot stability using a plasma system, another assay was used.  The 
modified CLoFAL assay derived from the methods published by Lisman et al, 2002 and 
Goldenberg et al, 2005 employs both clot formation and clot lysis.  Because this assay 
quantitatively measures the rate at which the clot is formed and lysed, it was used to 
analyse the rate at which the formed fibrin clots within a plasma system were being 
cleared in the presence of a standardised concentration of tpa.  This analysis is highly 
influenced by the biochemical composition of the plasma.   
 
Like the ROTEM assay, the CLoFAL assay also uses low TF to initiate clot formation 
and low tpa concentrations to initiate fibrinolysis.  The influence of coagulation factor 
deficiencies has previously been investigated (Goldenberg et al, 2005).  Fibrinogen and 
FVIII have been reported to influence the MP and T1 and hence the rate of clot lysis.  
ICU samples showed a prolonged time to the maximum peak, which is comparable to 
the CFT and MCF of the ROTEM assay.  In Figure 3.9, the CLoFAL analysis 
demonstrated a decreased response in the haemophiliac sample group but the ICU 
sample group demonstrated a similar pattern to the healthy volunteer group.  This is 
similar to what was observed in the clotting profile recorded with the ROTEM in that 
the MCF and the angle of the clot was enhanced.  The CLoFAL assay is a turbidimteric 
assay and therefore the rise and decline in absorbance corresponds to clot formation and 






 4.4 Fibrin architecture  
Recent studies have shown hat abnormal thrombin generation produces clots that have 
altered fibrin structure, changes that are associated with bleeding or thrombotic risk.  
Several factors influence clot formation (such as the presence of cells and their products 
such as soluble factors like TAFI and PAI-1) but the most important is the thrombin 
present during fibrin clot formation.  Very low concentrations of thrombin are sufficient 
to facilitate fibrinopepetide cleavages, resulting in fibrin polymerisation.  Low thrombin 
concentrations produce fibrin clots that are turbid and composed of thick, loosely-woven 
fibrin strands whereas higher fibrin concentrations produce thinner, more tightly packed 
fibrin strands (Wolberg, 2007).   
 
Fibrin plays two roles in fibrinolysis, it acts a both a substrate and a co-factor for 
plasmin, and may explain why clots with altered fibrin structure exhibit altered 
susceptibility to fibrinolysis.  Thinner fibrin fibres show a slower rate of tpa-mediated 
lysis, thereby reducing the rate of overall fibrinolysis in comparison to thicker fibres 
(Gabriel et al, 1992).  Consequently, clots with thinner fibres are more resistant to 
fibrinolysis, hence thicker fibrin fibres lyse slower than thin fibres.  However, because 
clots that are produced by low thrombin concentration are composed of thick fibres that 
are loosely woven, there will be less fibres in the clot, which makes the clot more 
susceptible to lysis.  High thrombin concentration clots have more tightly packed fibres 
with more individual strands.  Collectively, this means that even though plasmin is 
generated on individual fibrin fibres, its activity is rate-limited within the entre fibrin 
clot structure.   
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The way thrombin generates a clot has further been explained through the extrinsic and 
intrinsic activities (Wolberg, et al, 2005).  It is believed that low thrombin levels are 
produced during the extrinsic pathway and further on during coagulation, at the 
propagation step, higher concentration of thrombin are produced.  This means that the 
fibrin architecture is composed of a mixture of both thick and thin fibrin fibres.  This can 
be clearly explained in a haemophilia setting.  Deficiency of FVII or FIX causes a 
defective tenase complex.  The results in a defective propagation stage, which means 
that the clot formed is composed of the thick fibrin strands produced during the 
extrinsic-initiation production of low concentration thrombin.   Thick fibrin strands are 
more susceptible to fibrinolysis. 
Results of the CAT assay showed reduced thrombin generation in ICU samples.  
Reduced thrombin levels decrease the rate of fibrinopepetide release and therefore delay 
fibrin polymerisation.  Abnormal fibrin structure in the samples could render these clots 
susceptible to fibrinolysis.  The reduced thrombin generation may also limit the 
activation of TAFI in plasma, which further allows fibrinolysis.   
Recombinant activated FVII at high concentrations increases thrombin generation by 
directly activating FX.  This shortens the time taken to reach peak thrombin level.  ICU 
sample fibrin clots did not show an indication of lysis as was noted in the plasma fibrin 
clots from the healthy volunteers.  This is suggestive of a less porous, lysis- susceptible 
clot structure.  This may be because the fibrin strands are thinner and more compact with 
the overall clot structure.  The robustness of the clot may be increased by the presence of 
rFVIIa.  The high thrombi concentration may also influence TAFI activity, thus reducing 




The role of clot structure in the ICU sample is important in that depending on when 
fibrinolysis is initiated, it could be a good indicator for bleeding or thrombosis.  At the 
end of clot formation, both thick and thin fibres are present in the architectural structure.  
If clot lysis were begin after the clot is formed then the structure is likely to play a 
significant role in the stability of the clot formed and whether an anticoagulant or a 
procoagulant state is the likely outcome.  Alternatively, if fibrinolysis occurs before the 
clot is fully formed, then it is more likely to be the competitive rate of clot formation and 
clot lysis that determines how haemostasis occurs.  How which of these possibilities will 
occurs may depend on the clinical setting of the ICU individual and any other 
contributing factors to their clinical picture.  Therefore, the pattern of thrombin 
generation may determine the clot structure formed and therefore determine the rate of 
clot lysis although this still requires extensive studies in the setting of these research 




The aim of this study was to analyse the clotting status in ICU patient samples through 
use of global assay analysis.  This study has demonstrated that samples taken from ICU 
patients have abnormal clot formation and are susceptible to lysis, even in the presence 
of rFVIIa compared to their healthy volunteer counterparts.  The global assays were 
used in conjunction with other laboratory assays to profile clot formation and stability in 
the ICU samples.  Global assays activated by low TF showed that these ICU samples 
had a delayed activation of haemostasis but once initiated, thrombin and clot formation 
is comparable to that in healthy volunteers or somewhat enhanced.  The addition of 
rFVIIa only improved the initiation of clot formation but overall did not significantly 
improve the clotting profile in the ICU samples but this, however, does not mean that 
rFVIIa is ineffective in ICU samples.  Coagulation tests have been previously reported 
to show abnormal results in critically-ill patients (Collins et al, 2006) in the ICU and 
this has been shown in this study.   
Previous reports have shown that abnormal haemostasis is a common occurrence and 
that it not insignificant.  Haemostasis abnormalities contribute to mortality and 
morbidity and require thorough analysis to establish the underlying cause and to ensure 
that the correct intervention is carried out.  Routine coagulation tests are used, mostly 
prior to surgery and other invasive procedures. This is usually based on the assumption 
that these first-line tests will clinically predict the risk of bleeding.  However, first-line 
coagulation tests have limitations; especially clarification within a clinical setting.  
Routine coagulation tests may not be useful in a surgical and medical setting because 
they have limited sensitivity and specificity (Chee and Greaves, 2003) and this has been 
demonstrated in this study.  If analysis of haemostasis was based on the clotting screens 
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alone, coupled with the measured coagulation factors, then this study would have shown 
a high number of false positive ICU samples for abnormal coagulation.  Thus, even 
thought these samples showed abnormal results for coagulation factor and routine tests, 
global assay analysis demonstrated a normal clot formation profile after the clots were 
initiated and this did not tie in with the routine coagulation test results.  In other words, 
the clotting profile, despite a prolonged initiation in clot formation was similar to that 
observed in healthy volunteer sample group.  The haemophiliac sample group showed a 
more compromised clot profile overall and unlike, the ICU sample group, the clot 
profile in the haemophiliac sample group could be explained by their aetiology of the 
disorder.   
First, the data from whole blood analysis by thromboelastometry, which doubled as an 
indirect measure of thrombin generation, showed that there wasn’t a distinct difference 
between ICU and healthy volunteer samples.  In addition, this study showed that within 
a cellular system, the response to rFVIIa in the ICU sample group was comparable to 
that observed in the healthy volunteer group.  Even though both sample groups were 
responsive to the single rFVIIa dose, there was no distinct difference in the ROTEM 
parameters between the two groups.    The use of rFVIIa as a haemostatic tool has been 
well established in controlling bleeding in haemophiliacs with inhibitors and other 
coagulopathies (Hedner and Ingerslev, 1998).  Previous studies have shown that low-TF 
activated thromboelastometry is a suitable method for monitoring response to rFVIIa 
(Ingerslev, 2000).  For this study, rFVIIa demonstrated the capability to promote 
haemostasis in both whole blood and plasma samples from ICU patients.  The graphical 
display of measurable parameters allowed for analysis of the differences within the ICU 
sample group despite the fact that overall the ICU results were not all that 
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distinguishable from those observed in the healthy volunteer sample group.  Monitoring 
the effects of rFVIIa by recording continuous whole blood coagulation was a major 
advantage compared with the monitoring initiation of plasma clotting.  This may be 
because whole blood analysis was within a cellular and plasma protein system and this 
was a much better representation of what may be going on in vivo compared to 
analysing clotting in plasma.  The most noticeable effect of rFVIIa was reflected in the 
CT and the CFT of coagulation, thus the initiation of coagulation.  This study showed 
that variation in response to rFVIIa within the ICU sample group were variable might 
be influenced by several factors which require further analysis.  However, in this study, 
the ROTEM assay was a good method characterising phenotypic variance amongst ICU 
patients as well as detecting the response to rFVIIa in an in vitro setting.    
Plasma analysis using the CLoFAL assay proved useful in such a way that the first stage 
of the assay, the clot formation stage was corroborative to what the data demonstrated in 
the ROTEM assay.  During CLoFAL analysis, the ICU samples showed a prolonged 
time to the clot iniitation, as observed with the CT and CFT of the ROTEM assay and 
the lag timeof the CAT assay.    However once the clot initiated, it formed with a 
stability the was comparable to that observed in healthy volunteers samples.   This may 
be attributed to the fibrin structure of the clot that was formed in these plasma samples.  
The structure of the fibrin formed may be affected by both he pro- and anti-coagulant 
pathways in these samples, therefore any alteration occurring tin these pathways will 
affect the structure of the fibrin clot formed and subsequently its rate of lysis.  
 
Both the ROTEM and CLoFAL assays showed that even though the time taken to clot 
formation was prolonged, once activated, the clot structure was normal, or even 
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enhanced in the ICU samples, making both these global assays useful in depicting a 
more comprehensive picture of coagulation in ICU patient samples. The CLoFAL assay 
was able to analyse the stability of the fibrin clots formed in plasma samples in the 
presence of a lysing agent, tpa.  The prolonged clotting screens in ICU samples may be 
suggestive of an inability to initiate and sustain a stable clot.  In Section 3.4, it was 
demonstrated that fibrin clots in ICU plasma samples were not susceptibility to lysis and 
that they demonstrate a stabilised fibrin clot compared to the healthy volunteer group.  
The rate at which the fibrin clots lyse affects the stability of the clot formed, which may 
be attributed to the nature of the clot structure.  The clot structure depends on the 
presence and rate of thrombin production.  The data collected from this study is 
consistent with several factors that suggest a predisposition to abnormal thrombin 
production in the ICU samples.   This was further supported by prolonged clotting 
screens and the low coagulation factor levels.   
 
 
Areas of future analysis 
 
At present, one of the known common factors in patients on the ICU is that they have 
varied pathology and variable underlying and predisposing factors all which contribute 
to their clinical state and several of these factors can exist simultaneously.  Even though 
I was able to show, in this study, that the initiation stage of clot formation is prolonged 
in the ICU samples, and that the subsequent stages of coagulation is comparable to 
healthy volunteers sample coagulation or enhanced, this response was not unified within 
ICU group.  The response within this group was varied and there are various factors 
about ICU coagulation that this study did not address due to several limitations one of 
which was sample quantity.   
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One of the key areas of further study in the ICU sample group that links coagulation and 
fibrinolysis is the thrombi activatable fibrinolysis inhibitor (TAFI) pathway.  In the 
presence of high thrombin levels, TAFI is activated, which then suppresses plasminogen 
activation of plamsin and therefore prevents the degradation of the clot to soluble 
fibrinopeptides.   Previous reports have suggested that TAFI deficiency plays a 
significant role in the ICU setting (Meijers et al, 2000).  Its deficiency has been linked 
to predisposing to a bleeding diathesis because of an impaired capacity of the 
coagulation system to protect clots from lysis (Watanabe et al, 2001; Meijers et al, 
2000; Van Theil et al, 2001) although it has been reported that a decrease TAFI level 
does not increase the risk of plasma lysis (Lisman et al, 2001).  Studies have also shown 
that the ability of rFVIIa to stabilise coagulation in haemophiliacs with inhibitors is 
TAFI dependent (Lisman et al, 2002).  Investigating the role of TAFI may play a pivotal 
role in elaborating on the coagulation in critically-ill patients. 
Another area for further investigation is the fibrin clot formation structure in ICU 
samples.  A previous study was able to measure fibrin formation, turbidimetrically, by 
determining mass/strength ratio of the fibrin fibres formed in the clot.  By measuring the 
turbidity at a single wavelength, clot structure was determined under multiple 
conditions (Wolberg, 2007).  This study was able to demonstrate the nature and type of 
fibrin fibres formed within the clot will determine its susceptibility to plasma lysis.  The 
same approach can be applied to the ICU sample group. 
Low-TF activated global assays in this study have demonstrated that samples from ICU 
patients have delayed activation coagulation but once initiated can be normal or 
enhanced.  This further clarifies current reports on how routine coagulation tests are not 
accurate predictors of haemostasis outcome in patients with complex coagulation.   
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However, several investigations need to be carried out to link relevant end points of 
either bleeding or thrombosis to these global assays with ICU patients so that a broader 
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 Assay development of an in vitro assay that utilises a single tissue factor 
concentration [TF] for optimal clot formation 
 
The TF was added to operate as a physiological activator.  The main reason for this was 
to ensure that the TF concentration added to the plasma was sufficient to trigger clot 
formation.  This test aimed to locate the lowest threshold TF concentration to initiate 
clotting in these samples.   
 
Titration of various innovin TF concentrations were analysed using pooled platelet poor 
plasma and ROTEM assay parameters measured.  Previously, there have been variations 
in TF concentrations that are standardised among investigation groups for processing 
and assay conditions (Sorensen et al, 2003 (a) and Sorensen et al, 2004 (b)).  Therefore, 
in light of this, a single exogenous optimal TF concentration was standardised to 
activate clot formation on samples analysed on the ROTEM.  
 
TF titration was performed using multiple dilutions (Table i) of the TF stock solution 
(9.3nM) ranging from 1:5 dilution (~1.86pM) to 1:20,000 dilution (~0.465pm) as 
starting concentrations.  In each step, 20l of the respective TF concentration was added 
to 300l of pooled platelet poor plasma (PPP) obtained from healthy volunteers and the 





Dilution ~ Starting concentration, 
M 
~ final TF concentration, 
M in 340µl of plasma 
1:5 1860 109.4 
1:10 930 54.7 
1:25 372 21.9 
1:50 186 10.9 
1:100 93 5.5 
1:500 18.6 1.1 
1:1000 9.3 0.5 
1:2000 4.65 0.27 
1:5000 1.86 0.11 
1:10,000 0.93 0.05 
1:20,000 0.465 0.03 
Table i TF titrations with corresponding concentrations in pM 
 
Method: Plasma samples were run using the ROTEM assay and the respective TF added 






















Figure i Tissue factor concentrations and the times taken to clot formation in normal platelet poor 
pooled plasma, results are expressed as the mean of triplicates and the bar represents the mean of 
the triplicates 
 
The results of the clotting time in Figure i showed that there is no significant change in 
the CT up to 0.27M.  CT decreased at the TF concentration of 0.50M when the 
clotting time was reduced in the plasma sample.  After this point, clotting times follow a 
decline and reach a plateau phase at a concentration of 10.90M that continues for the 
reminder of the TF concentrations.  Statistically, there was no significant difference 
between clotting times of endogenous TF in the sample and concentrations from 
0.03M - 0.27M.  However, the variation in TF concentration noted between 0.50M 
– 109.4M showed a statistical significance in clotting times (p<0.01 ANOVA).  The 













































































of 0.50M.  The concentration of TF used to trigger clot formation in this plasma assay 
was 0.5M.   
 
Appendix ii 
 Assay development of an in vitro assay that utilises a single volume of 
rFVIIa for the purpose of analysing fibrin clot responses to rFVIIa  
 
In order to investigate the response of the analysis sample to rFVIIa, a volume titration 
of 8.82ng/ml was carried out to ascertain a standard volume of rFVIIa to add to the 
sample during global assay analysis.  The changes in plasma clotting profile on the 
ROTEM assay were analysed the in the presence of rFVIIa. 
 
Method: ROTEM assays were conducted with the infusion of rFVIIa at a concentration 
of 0.6mg/ml (standard therapeutic concentration per 90kg weight) at variable volumes 
and fibrin clot formation recorded.  rFVIIa volumes were tested on normal pooled 












Figure ii rFVIIa volume titration in normal platelet poor pooled plasma, results are expressed as 
the mean of triplicates and the bar represents the mean of the triplicates 
 
 
Results: Clotting time was proportional to the volume of rFVIIa added to the plasma 
samples up to a volume of 5.0l (p<0.0001)..  The maximum amplitude and clot angles 
(not shown) did not show any significant trends that correlate with the titration volumes 
and reach a plateau at much lower volumes (0.5l), which may the influence of rFVIIa 
in a plasma system (see section 3.4).  This study showed that the optimal volume of 





 Assay development of an in vitro assay that utilises a single tpa 
concentration for optimal clot lysis 
 
The tpa used was added to operate as a physiological activator of clot lysis.  This test 
aimed to locate the optimal threshold tpa concentration to initiate lysis in these samples.  
This study, designed to optimise a tpa concentration, was carried out by titration of 2-
chain tpa concentrations and their influence on clot lysis using the CLoFAL assay on 
normal platelet poor plasma was analysed.  The tpa titrations was were diluted from a 
tpa stock solution (1mg/ml) ranging from starting concentrations 20µg/ml to 500ng/ml 
dilutions.   
 
Figure iii tpa titration in normal platelet poor pooled plasma, results are expressed as the mean of 
triplicates and the bar represents the mean of the triplicates. AU = Absorbance units 
 
The results shown in Figure iii demonstrate that the increase in concentration of tpa 
induced fibrin clot lysis.  3µg/ml of tpa allowed for clot formation and induce clot lysis.  
Concentrations of tpa higher than 3µg/ml induced clot lysis too early or the toa 
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concetrations lower than 3µg/ml did not induce lysis.   For the CLoFAL assay the 
concetrtion of tpa that was employed to indice lysis was 3µg/ml.   
 
Appendix iv 
 Assay development of an in vitro assay that utilises a single PL 
concentration for optimal clot lysis 
 
The CLoFAL assay involved the addition of 25µl of phospholipid (PL) to the plasma or 
reaction lysis buffer mixture, respectively.  Therefore a titration of PL concentrations 
was performed to determine a concentration for the assay.   
The results in Figure iv show the plasma turbidity is inversely proportional to the PL 
concentration.  The concentration of PL that gave the highest signal of absorbance was 
at 100µM. 100µM concentration of PL was used in the CLoFAL assay, giving a final 
concentration of 12.5µM. 
 
Figure iv PL titration in normal platelet poor pooled plasma, results are expressed as the mean of 
triplicates and the bar represents the mean of the triplicates AU = Absorbance units 
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